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Overview: Hypertensive disorders in pregnancy (HDP), of which the most common is pre-
eclampsia (PE), are a leading cause of maternal and foetal morbidity and mortality 
worldwide. Despite extensive research, no clear cause or mechanism for HDP has been 
discovered. Human papillomavirus (HPV) has transformative abilities among many cell 
types and alters key pathways in reproductive cells essential for embryo implantation and 
placental development in vitro. It has also been consistently found in the placentae, 
especially in those complicated by PE. These findings suggest HPV may not be only a 
bystander in complicated pregnancies, but has a direct role in abnormal placental 
development. Whether HPV genes such as E6/E7 that encode the E6 and E7 proteins, which 
affect trophoblast function in vitro, are expressed in vivo is unknown. Understanding gene 
expression profiles in placental tissue is complicated by the wide variety of cell types 
present and their distinct genetic origins. This study used RNAscope® to investigate 
whether in situ based techniques could identify HPV E6/E7 expression differences in 
placentas from a cohort of Japanese women. A second aspect of this study used 
RNAscope® to investigate if genes found to be differentially methylated in the cohort were 
associated with HDP. NOTCH2 and CMIP were chosen. 
 
Methods: Fifteen placenta from uncomplicated pregnancies, sixteen placenta from 
pregnancies complicated by HDP, and six additional cases of non-HDP pathologies, were 
converted to FFPE slides and examined using RNAScope®, or immunohistochemistry. 
RNAscope® assays to determine RNA quality, non-specific staining, HPV high-risk E6/E7, 
HPV low-risk E6/E7 and NOTCH2 were undertaken, along with immunohistochemistry for 
CMIP. Results were compared between the HDP and control groups.  
 
	 ii	
Results: The majority of placentas from the HDP (n=15/16, 94%) and the control (n=11/15, 
73%) cohorts had sufficient RNA quality. In the HDP group, six cases (n=6/15) tested 
positive for high risk HPV E6/E7 (40%), and five tested positive for low risk HPV E6/E7 
(33%). None of the control cases tested positive for high risk HPV (0%) or low risk HPV 
(0%). Expression of HPV high and low risk E6/E7 was increased in the HDP compared to 
the control cohort (p<0.05). The NOTCH2 assay was optimised and NOTCH2 was 
expressed heterogeneously between neighbouring cells in individual cases, but the number 
of cases tested was too low for statistical power. The CMIP assay did not work, requiring 
further optimisation. 
 
Conclusion: This study provides evidence that HPV high and low risk E6/E7 is expressed 
in the placenta of pregnancies complicated by HDP. These results add validity that HPV 
may affect placental function by showing HPV gene expression is active in the HDP 
affected placenta. Further research is needed to understand why transcriptionally active 
HPV E6/E7, of both high and low risk types, would be present in the developing and term 
placenta. In addition, RNAscope® proved viable for visualising cell types to target for 
further sequencing, which could be used to determine if one cell population is more 
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The placenta is the only temporary organ that humans develop. It is critical to support early 
human life and is unique in many ways. It is comprised of two genetically distinct regions: 
a foetal region containing foetal DNA, and a decidual region containing maternal DNA. 
The placenta has several critically important functions, including supplying the foetus with 
nutrients, filtering waste from foetal blood, and providing an extra selective barrier that 
assists the immune system and prevents the absorption of toxins by the foetus. The placenta 
can also regulate the foetus’ internal environment through encouraging the production of 
amniotic fluid, producing hormones that influence both foetal and maternal development, 
and thermoregulation (1). The autonomous actions of the placenta to sustain life make this 
multi-functional organ key to a successful pregnancy.  
 
When the placenta does not function correctly, complications in pregnancy arise. Often 
abnormal functioning of the placenta can be linked to anatomical or molecular pathologies 
(2–8). Like other tissues of embryonic origin, the placenta has a very undifferentiated cell 
population, enabling it to be more strongly influenced by disease and environmental 
conditions. Hypertensive disorders of pregnancy (HDP), of which pre-eclampsia (PE) is the 
most prevalent, is a condition by which maternal blood pressure increases and placental 
function decreases, and can lead to serious morbidity and mortality for the mother and 
foetus. Despite their commonalities, the pathophysiology remains elusive.  
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1.1 The Placenta 
1.1.1 Development of the placenta 
Placentas are a defining characteristic of placental mammals, but can also be found 
in marsupials and some non-mammals (9). The placenta functions as a foetomaternal organ 
with two components: the chorion frondosum (the foetal placenta), which develops from 
the blastocyst that forms the foetus, and the decidua basalis (the maternal placenta), which 
develops from the maternal uterine tissue. The synergy in development of these two 
portions creates a highly vascularised interface where nutrients, gases, wastes, immune 
products and even some cells themselves, can cross the semi-permeable barrier which is 
only a few cell layers thick (8). Upon birth, the placenta is expelled from the body by 
contraction of the uterus (8).  
 
During human development, between the morula and blastocyst stages (days 4–5 post-
conception), the trophoblast is the first cell lineage to differentiate. After establishment of 
the trophoblast, the blastocyst consists of an inner cell mass that is surrounded by a single 
layer of mononucleated trophoblasts. This outer layer surrounds not only the embryoblast, 
but also the blastocoel (the blastocyst cavity). Later in pregnancy, the trophoblast gives rise 
to larger parts of the placenta and foetal membranes, while the inner cell mass gives rise to 
the embryo, the umbilical cord, and the placental mesenchyme. The latter is derived from 
extraembryonic mesoderm outgrowing from the early embryo. At about days 6–7 post-
conception, the blastocyst hatches from the zona pellucida and attaches to the uterine 
epithelium – it is at this stage that the formation of the placenta begins (8). 
 
The localisation of the inner cell mass defines the part of the trophoblast cover that makes 
the final attachment of the blastocyst to the uterine epithelium (Figure 1). Only those 
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trophoblasts overlying the inner cell mass (referred to as polar trophoblast) seem to be able 
to establish implantation (8). Rotation of the blastocyst at this stage can lead to failure of 
pregnancy due to reduced contact of the polar trophoblast to the uterine epithelium. It has 
been described that varying the orientation of the blastocyst at the time of attachment and 
implantation, such as through the use of in vitro fertilisation techniques, results in 
abnormalities of the umbilical cord inserting into the chorionic plate (10,11). 
 
As soon as the blastocyst has firmly attached to the uterine epithelium, the polar trophoblast 
undergoes the next differentiation step, syncytial fusion of mononucleated cells to generate 
the first oligonucleated syncytiotrophoblast. At this stage of development, the 
syncytiotrophoblast displays an invasive phenotype, and only by means of this 
syncytiotrophoblast is the blastocyst able to penetrate the uterine epithelium (12–14).  
 
During the next few days, the early embryo embeds itself into the decidual stroma with the 
syncytiotrophoblast forming a complete mantle surrounding the embryo. The remaining 
mononucleated trophoblasts are now referred to as cytotrophoblasts, which are found 
behind the syncytiotrophoblast, they do not contact maternal tissues. The cytotrophoblasts 
act as stem cells, which rapidly divide and subsequently fuse with the syncytiotrophoblast, 
resulting in a continuous expansion of the latter (8). 
 
From eight days after conception, the remaining syncytiotrophoblastic mass coalesces 
around fluid-filled spaces, creating lacunae (spaces) and trabeculae (stalks) which are of 
importance for the further development of the villous trees of the placenta (Figure 1). As 
soon as the lacunae have developed, the three fundamental zones of the placenta can be 
defined: 1) the early chorionic plate facing the embryo, 2) the lacunar system together with 
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the trabeculae developing into the intervillous space and the villous trees, and 3) the 
primitive basal plate in contact with the maternal endometrium. During implantation, the 
cytotrophoblast invades the interstitium of the endometrium by pushing through the 
syncytiotrophoblast and forming columns which come into contact with maternal capillaries 












Figure 1. The blastocyst; days 8-12. 
An inner cell mass of embryonic cells surrounded by trophoblasts. As trophoblasts invade the 
endometrium in the second week after conception, they differentiate in to invasive EVT. At the areas 



















Figure 2: The blastocyst; day 16. 
By day 16, the embryo has become firmly implanted and surrounded by endometrium (not pictured) 
while still maintaining a barrier of syncytiotrophoblast. Trabeculae (stalks) of trophoblasts have 
created spaces (lacunae) for maternal blood to flow into. Exchanged of maternal and foetal 
products takes place by transport through the syncytiotrophoblast (16). 
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At around 8-10 weeks gestation, cytotrophoblasts differentiate into extravillous 
trophoblasts (EVT) which penetrate uterine spiral arteries, replacing the endothelial lining 
and musculoelastic tissues to create low-resistance vessels (Figure 3). EVT are trophoblasts 
that exist outside of the basal plate, and are considered stem cells, dividing and replacing 
cells as the embryo moves deeper through the endometrium and into the myometrium. EVT 
adhere to the walls of uterine spiral arteries before migrating into the vessels and replacing 
the media smooth muscle cells (17). These are now called endovascular villous trophoblasts 
(ENVT). This allows maternal blood to flow into the placental lacunae without the pressure 
that might otherwise damage the tissue. By 20 weeks, this spiral artery remodelling ceases 
and if adequate maternal blood supply into the placenta has not been fully established, 
placental insufficiency occurs (18). It has been shown that in PE and intrauterine growth 
restriction (IUGR), invasion of ENVT fall short of the myometrium (17–21). 
 
Throughout the remodelling process, the decidualised endometrium combines with the 







Figure 3: Cytotrophoblasts invade the lumen of maternal spiral arteries.  
This image shows the non-pregnant uterine spiral artery, the shallow remodelling of uterine spiral 
arteries by endovascular villous trophoblasts (ENVT) in PE and the remodelling by ENVT in normal 
pregnancies that invade well into the myometrium. ENVT replace the smooth muscle and 
endothelium allowing for low and consistent pressure of blood flow around the foetal vessels. 
Extravillous trophoblasts (EVT) and uterine natural killer cells (NK cell) are also shown (22).  
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1.1.2 Anatomy of the formed placenta 
The formed placenta consists of thick layers of cells mixed with the decidualised 
endometrium of the maternal uterus. This layer, called the decidua basalis (Figure 4), 
contains a protective layer of decidualised endometrial cells around trophoblast lined 
remodelled spiral arteries. The maternal blood supply that infiltrates the decidua basalis 
carves channels through the decidua and drain back out via uterine veins. The decidua has 
a histologically-distinct appearance, with its large polygonal decidual cells, originating 
from the endometrial cells which have undergone decidualisation, and predominantly large 
endometrial granular leukocytes as well as polynuclear leukocytes and B cells are scant. 










Figure 4: Gross anatomy of the placenta.  
Macroscopic divisions of the placenta including the maternal layer (decidua basalis) and foetal 
layer (chorion frondosum and chorionic villous) (16).  
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Between the decidua basalis and the chorion frondosum (Figure 5) is a basal plate 
consisting of EVT and fibrinoid deposits that are generated over the course of gestation 
(23). The basal plate is thin, providing a barrier between the maternal and foetal villi but 
allowing for the exchange of gases and metabolic products. Increased deposition of fibrin 
is a pathological finding associated with complications in pregnancy (11,24).  
 
The foetal layer, chorion frondosum, contains villi extending from the umbilical arteries 
and a vein infiltrating a layer of cytotrophoblasts. Directly lining the foetal vessels is the 
syncytiotrophoblast: a protoplasmic cell devoid of boundaries which is continuous along 
the length of the vessels. As the cytotrophoblasts undergo apoptosis over the course of their 
life cycle, their nucleic material is absorbed by the syncytiotrophoblast to avoid detection 
of the foreign genetic material by the maternal immune system which could have morbid 
consequences. The syncytiotrophoblast bundles the nuclei together and surrounds them in 
a membrane before secreting them into the maternal blood. The syncytiotrophoblast is 
unique in that it suppresses the expression of HLA-A and HLA-B. Human Leucocyte 
Antigens (HLA) are a gene complex encoding the major histocompatibility complex 
(MHC) proteins in humans. These genes are polymorphic, allowing for a wide range of 
expression and therefore activation of the many parts of the immune system. HLA-A 
specifically stabilises the CD8 molecule and activates CD8+ cytotoxic T cells (25), while 
HLA-B produces class II molecules that allow cells to present antigens to immune reactive 
cells (26,27). Lack of expression of these important immunological proteins allows the 
syncytiotrophoblast to provide an immunologically neutral barrier, preventing immune 
degradation of itself and movement of immune cells across the barrier into the foetal side 








Figure 5: Annotated microscopic anatomy of the developing placenta (week 8). 
Microscopic divisions of the foetomaternal junction (basal plate) in the early stages of placental 
development (week 8). Columns (trabeculae) of invading trophoblasts are visible, multi-nucleated 
syncytiotrophoblast has formed a shell around these and decidualisation of the endometrium has 




The largest extensions of the foetal vessels run along the surface of the foetal layer before 
diving down into the villi. These vessels are covered by a layer of chorionic membrane, 
which is in turn covered by a layer of amniotic membrane. The amniotic membrane 
surrounds the foetus and contains the amniotic fluid. The amniotic membrane contains a 
single layer of flattened cells of ectodermal origin while the chorionic membrane is 
composed of similar cells but of mesodermal origin (29). The stalk where the membranes 
arise from the placenta also contains the umbilical arteries and vein. The two umbilical 
arteries carry unoxygenated, nutrient-depleted blood away from the foetus while the one 
umbilical vein carries oxygenated, nutrient rich blood towards the foetus. The three major 
vessels are coiled within the umbilical cord which also contains a gelatinous substance 
called Wharton’s Jelly which surrounds and protects the vessels from kinks or knots that 
would obstruct blood flow. This is all surrounded by an inner layer of irregularly arranged 
ground substance and cells and an outer layer of circularly arranged smooth muscle (8). 
Further information on cell types specific to the placenta are found in Table 1.  
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Table 1: Cell types of the placenta. 
Name: Layer:  Cell origins: 
Cell Type: 
Function:  




Differentiation of endometrial cells that causes a gradual 
and profound alteration in gene expression, cellular 
functions, and tissue remodelling until the complete 
formation of a placenta during pregnancy (30).  




Innate lymphoid cells. During pregnancy, NK cells are 
the most abundant lymphocytes in the uterus at the 
maternal-foetal interface and are involved in placental 
vascular remodelling (31). 
Endothelial cells Decidual Mesoderm 
Epithelial 
Cells that line the interior surface of blood 
vessels and lymphatic vessels exert endocrine and 
paracrine functions to regulate blood flow. They also 
protect vessels from vascular and pressure injury, 
conduct fluid filtration, maintain blood vessel tone, 
contribute to haemostasis and neutrophil recruitment 
(32).  




Vascular smooth muscle responds to local and central 
metabolites and nerve signalling to contract or relax to 
change; the volume of blood vessels and the local blood 
pressure. Together these redistribute blood within the 
body to areas where it is needed (32).  




Stem cells for all trophoblasts. Cytotrophoblast surround 
and protect the foetus. Instead of undergoing normal 
apoptosis, they merge with neighbouring CTB to form 







Found in the decidua basalis, they downregulate natural 
killer cell responses and adhere to and invade into the 







Are extravascular trophoblasts that invade uterine spiral 
arteries causing loss of the endothelial lining and 
musculoelastic tissue in these vessels (placental vascular 
remodelling). This loss of elasticity and increase in the 
luminal diameter of the spiral arteries creates low 
resistance vascular channels to meet the gestational 









Regulates the complex biomolecular interactions 
between the fetus and mother; providing structural and 
biochemical barriers between the maternal and foetal 
compartments during pregnancy and produces numerous 
growth factors and hormones that support and regulate 
placental and foetal development and growth (15). 
Perinatal mesenchymal 








Mostly present in the first 8-20 weeks of gestation. 
Classically undifferentiated, but regulate immune 
tolerance in the maternal-foetal interface by supressing 
activation and cytotoxicity of uNKC’s while increasing 
anti-inflammatory macrophage recruitment (33). 
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1.1.3 Functions of the placenta 
The functions of the placenta can be divided into four main categories: metabolic, gas 
exchange, hormonal and protective. The metabolic functions of the placenta pertain to the 
structure of the layers between the maternal and foetal blood supplies and how these create 
a semi-permeable barrier. The barrier allows for the exchange of metabolites and nutrients 
so that the foetal blood is being maintained in homeostasis by the concentration of 
metabolites and nutrients in the maternal blood. This means waste products produced by 
the foetus are also exchanged across the barrier into the maternal supply as the foetus does 
not have the ability to remove its own wastes. The barrier is able to protect against some 
harmful metabolites by not producing channels that allow these to cross into the foetal 
supply, however, many organic chemicals contain similar functional regions as important 
metabolites of somatic origin which allows them passage into the foetal circulation.  
 
Exchange of gases also occurs across the semi-permeable barrier of the placenta. This too 
would exist in homeostasis with the maternal blood if it weren’t for the uniqueness of foetal 
haemoglobins. To create the driving force that allows for oxygen to be exchanged from 
maternal to foetal haemoglobin, foetal haemoglobin is comprised of two alpha and two 
gamma sub-types. Among haemoglobin sub-types, gamma has the highest affinity for 
oxygen. A higher affinity for oxygen, and the thin layer between the maternal and foetal 
supply creates the optimal conditions for exchange of all gases in the placenta. This 
exchange can occur without the need for absolute contact between the two blood supplies, 
which would lead to the maternal body falsely identifying the foetus as a threat.  
 
The hormonal function of the placenta is extremely important for signalling the maternal 
body to undergo the physiological changes necessary to carry the foetus to term. Shortly 
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after implantation, the placenta produces Human Chorionic Gonadotrophin (HCG) which 
stops menses and development of any follicles. HCG then stimulates the corpus luteum to 
continue to secrete progesterone and estrogen. Progesterone stimulates secretions in the 
fallopian tubes that help the embryo move into the uterus and stimulates uterine secretions 
that nourish the embryo until the placenta has formed. Estrogen increases proliferation of 
the endometrium to create sufficiently vascularised tissue for the embryo to implant into. 
Continuation of both of these hormones are important in successful implantation. The 
placenta also secretes Human Placental Lactogen (hPL) which acts alongside growth 
hormone increasing Insulin-like Growth Factor (IGF) to increase nutrient, and specifically 
glucose, secretion into the maternal blood. This is then taken up by the rapidly developing 
foetus. In addition, hPL specifically targets the development of the foetus by acting on 
lactogenic receptors to modulate embryonic development, metabolism and stimulate 
production of IGF, insulin, surfactant and adrenocortical hormones (34).  
 
Lastly the placenta has protective functions for the foetus which are both macro- and 
microscopic. The placenta indirectly produces amniotic fluid by acting as a central point 
for maternal blood supply within the uterus. Hydrostatic and osmotic forces in the maternal 
supply drive fluid out of the maternal blood, into the foetal villi and then out again through 
the membranes into the cavity surrounding the foetus. Amniotic fluid then bathes the foetus 
providing mechanical protection from the maternal body’s movements. The foetus also 
breathes and swallows the fluid. Once the foetus has absorbed the fluid, wastes will be 
exchanged via the blood and the remainder will be urinated out, back into the amniotic fluid 
surrounding it. Abnormalities in implantation and increases in maternal blood pressure can 
lead to low and high fluid volumes respectively.  
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The microscopic protective functions of the placenta, as have been mentioned above, relate 
to the expression variance of immunological proteins HLA-A and HLA-B. The continuous 
syncytiotrophoblast prevents the invasion of immune cells of maternal origin into the foetal 
tissue when the foreign DNA and proteins would inevitably trigger catastrophic immune 
responses. Syncytiotrophoblasts show no HLA variation staining on 
immunohistochemistry, but foetal cells venturing into the decidua basalis, such as the EVT 
trophoblasts, stain predominantly for HLA-G and HLA-E. HLA-G and HLA-E are two non-
classical sub-types that are thought to be involved in the induction of immune tolerance by 
acting as ligands for inhibitory receptors present on NK cells and macrophages (27). This 
leaves the barrier immunologically inert, with cells beyond this more inclined to 




1.2 Hypertensive disorders of pregnancy 
1.2.1 Defining the hypertensive disorders of pregnancy 
Hypertensive disorders of pregnancy are characterised by hypertension but differ based on 
accompanying clinical presentation and worsening pathology (Appendix 7.1). Gestational 
Hypertension (GH), is a condition of pregnancy characterised by raised systolic and 
diastolic blood pressure. It may exist in isolation and present no further pathology, but is 
associated with IUGR, maternal or foetal morbidity and mortality (35). Pre-eclampsia (PE), 
previously known as Toxaemia, is a condition of pregnancy characterised by raised systolic 
and diastolic blood pressure and coinciding symptoms of proteinuria, vision changes, intra-
uterine growth restriction, abnormal liver function, and haematological disturbances (36). 
PE affects approximately 8% of first-time pregnancies and around eight million mother-
infant pairs each year (37,38). In the developing world, severe forms of PE and eclampsia 
are more common, ranging from a low of 4% of all deliveries to as high as 18% in parts of 
Africa (39). Worldwide, more than ten million women will develop PE and 76,000 will die 
from this, or a related hypertensive disorder, each year (40). A review in 2009 showed the 
foetal mortality rate to be extremely high at 500,000 per year due to associated 
complications from PE (41). The condition can only be treated effectively by delivery of 
the foetus and placenta, often prematurely. Premature deliveries are both physically and 
emotionally traumatic for both the mother and child, and can lead to life-long morbidity in 
neonates. PE is also often coupled with IUGR leading to smaller birth weight babies, than 
is typical for their gestation, whom are then further impacted by being delivered premature. 
Prematurity is the leading cause of death in infants with those surviving at a greatly 
increased risk of co-morbidities such as neurodevelopmental delay, chronic respiratory 
conditions, necrotising enterocolitis, brain haemorrhage, infection, vision and hearing loss, 
and complications relating to the circumstances in which they were born (e.g. maternal 
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infection, low birthweight, trauma, and gestational diabetes) (42). PE is a distinctly human 
disease making it difficult to study in models by other species, however hypertensive 
disorders with wider organ involvement have been induced in mouse models (43,44).  
 
GH can exist without progressing to PE, however PE can progress to more serious 
conditions such as eclampsia (characterised by seizures), or a variant characterised by 
hypertension, elevated liver enzymes and low platelets called HELLP syndrome, which too 




1.2.2 Impact and treatment of hypertensive disorders of pregnancy 
GH can be managed with medications, however PE can require more intensive treatment 
and inpatient monitoring. Severe PE, eclampsia and HELLP syndrome can only be treated 
through delivery of the foetus, often pre-term (Appendix 7.2) (45).  
 
The long term consequences of PE mainly involve disorders of the circulatory and renal 
systems (Table 2) but some evidence exists to suggest that cognitive impairment can persist 
between three and eight months post-delivery (36). Women who suffered from severe PE 
and eclampsia had impaired memory scores, unrelated to depression, anxiety or attention 
scores. Women also self-reported cognitive impairment and visual changes for years post-
delivery (36). As well as this, children born to a pregnancy complicated by PE have 
increased cardiovascular risk factors from an early age. A systematic review looking at 
cardiovascular risk factors in the offspring of pregnancies affected by PE found an increase 
in systolic blood pressure of 5.17 mm Hg (95% CI 1.60-8.73), and an increase in diastolic 
blood pressure of 4.06 mm Hg (95% CI 0.67-7.44) (46). There was also weak, inconsistent 
evidence that hypertensive disorders of pregnancy may be associated with an increase in 
adverse paediatric neurodevelopmental effects, such as inattention and externalizing 
















Table 2: Long term health complications associated with pre-eclampsia. 
Medical Condition Relative Risk [95% CI] 
Chronic Hypertension  3.70 [2.70-5.05] 
Ischaemic Heart Disease   2.16 [1.86-2.52] 
Cerebrovascular Disease  1.81 [1.45-2.27] 
Peripheral Vascular Disease  1.87 [0.94-3.73] 
Deep Vein Thrombosis  1.79 [1.37-2.33] 
End Stage Renal Disease  4.3 [3.3-5.6] 
Type II Diabetes  1.86 [1.22-2.84] 
Elevated TSH  1.7 [1.1-1.7] 
All Cancer  0.96 [0.73-1.27] 




1.2.3 Risk factors for hypertensive disorders of pregnancy 
Much of the research around HDP and PE has focused on determining it’s cause. The 
Society of Obstetric Medicine of Australia & New Zealand (SOMANZ) believe “it is likely 
that development of PE requires a combination of underlying susceptibility and a triggering 
event” (36). Many susceptibility factors for PE have been identified (Table 3). However, as 
for all medical conditions, the absolute risk for an individual will be determined by a 
combination of these and other predisposing or protective factors. To date, no adequately 
accurate predictive tool, using either clinical or laboratory markers, has been developed, 











Table 3: Risk factors for pre-eclampsia. 
Risk Factor Unadjusted Relative Risk [95% CI] 
Nulliparity 2.9 [1.3-6.6] 
Multiple pregnancy   2.9 [1.3-6.6] 
Previous history of PE  7.2 [5.9-8.8] 
Family history of PE  2.9 [1.7-4.9] 
Overweight BMI 25-29.9 1.7 [1.2-2.4] 
Obese BMI >30 2.7 [1.7-4.4] 
Age ≥ 40  2.0 [1.3-2.9] 
Systolic BP>130mmHg before 20 weeks   2.4 [1.8-3.2] 
Diastolic BP >80mmHg before 20 weeks  1.4 [1.0-1.9] 
Antiphospholipid syndrome  9.7 [4.3-21.8] 
Pre-existing diabetes 3.6 [2.5-5] 
Other risk factors  Underlying renal disease, Chronic 
autoimmune disease, Interpregnancy interval 
>10 years 




1.2.4 Recent research related to hypertensive disorders of pregnancy 
Research into the cause of HDP’s has developed over time into three distinct hypotheses: 
1) Haematological origin of disease,  
2) Genetic origin of disease,  
3) Inflammatory/pathogen-induced disease.  
 
1.2.4.1 Haematological origin of disease: 
Originally PE was thought to be a disease caused by poor vessel differentiation at 
implantation or by poor function of the maternal cardiovascular system. In 1985, Walsh et 
al., hypothesised that the production of prostacyclin and thromboxane was altered in the 
pre-eclamptic placenta compared to that of the normal placenta (47). Prostacyclin acts as 
an antagonist for the vasoconstricting, platelet-aggregating, and uterine-activating actions 
of thromboxane, these features being characteristics of some of the other disorders in the 
HDP group; thrombocytopenia and premature labour or abruption. They found production 
of thromboxane was significantly increased in pre-eclamptic versus normal placental tissue, 
whereas the production of prostacyclin was significantly decreased (47). This provided 
evidence that some of the symptoms of PE could be attributed to the significantly high 
presence of thromboxane, but this finding alone does not attribute a causation.    
 
In 1989, Roberts et al. hypothesised the cause of PE to likely be as the result of endothelial 
cell disorder, citing that more conducive research on factors of the disease other than the 
hypertensive component, needed study (48). The endothelial cell’s function when injured 
is to; reduce the synthesis of vasodilating agents, increase the production of 
vasoconstrictors, impair synthesis of endogenous anticoagulants, and increase procoagulant 
production. Therefore, it seems plausible that dysfunction or damage to these cells could 
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induce disease. They included that glomerular endotheliosis, an associated thrombotic 
microangiopathy of the glomerulus in PE (49), was sufficient evidence to say that 
endothelial injury existed. This led to them to propose that poorly perfused placenta may 
release a factor(s) into the systemic circulation that injures endothelial cells, specifically at 
the glomerulus. However, they did not elaborate on what factor this may be or why it 
originated from the placenta.  
 
Later in 1993, Ward et al. successfully published in Nature the discovery of the molecular 
variant of angiotensinogen, T235, being significantly associated with diagnosed PE (50). 
They detailed how the variant caused increased concentration of plasma or tissue 
angiotensinogen and could lead to increased baseline or reactive production of angiotensin 
II (ATII). Over years, chronic stimulation by ATII would activate autoregulatory 
mechanisms, increasing vascular tone and promoting vascular hypertrophy. This vascular 
hypertrophy would restrict the expansion of plasma fluid volume (40-50% over the course 
of normal pregnancies), triggering an imbalance between the vasodilatory mechanisms and 
the renin-angiotensin system, and causing the symptoms seen in PE relating to haemostatic 
regulation and glomerular malfunction. The variant was identified as having a significantly 
greater frequency in non-Caucasians (0.87) than in Caucasians (0.50, X\ = 33.6, p <0.0001), 
and gave notion to the identified affiliation in familial pedigrees.  
 
PE also occurs outside of the realms of normal pregnancy. Molar pregnancies (or 
hydatidiform molar pregnancies) are associated with early onset PE (51). Kanter et al. 
studied hydatidiform molar pregnancies, which are caused by absence of maternal nuclei in 
a developing embryo (51). They performed a case-control analysis of partial, complete, and 
invasive moles versus normal first-trimester placentas finding molar placentas had 
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significantly more staining than controls of fms-like tyrosine kinase receptor 1 (Flt1) and 
its soluble form (sFlt1). Flt1 is an endogenous anti-angiogenic protein that enters the 
maternal circulation after being overproduced in the placenta and it is believed this may be 
the cause of hypertension, renal lesions and glomerulopathy that leads to proteinuria (52–
54). As well as this, the soluble factor (sFlt) antagonizes free maternal circulating levels of 
angiogenic proteins such as free vascular endothelial growth factor (VEGF) and free 
placental growth factor (PlGF), which are critical for endothelial growth, differentiation, 
vascular integrity, decreasing vascular resistance and blood pressure (52). 
 
Research continued in pockets of the world without a consistent theme emerging, and in 
1998, a summary of the current aetiologies and concepts of PE was published by Dekker et 
al., identifying the four most significant hypotheses of the time. The first two of these were: 
1) Placental ischemia is related to endothelial cell dysfunction and 2) Toxicity caused by 
overloading albumin with very low-density lipoproteins, mobilised in pregnancy in 
response to increased energy demands, was reducing the liver’s capacity to detoxify (19). 
 
1.2.4.2 Genetic origin of disease: 
In the early 2000’s there was an insurgence of research relating to finding a distinct genetic 
basis for disease. Research at the time focused mainly on the presence and absence of alleles 
to implicate their role in pathology and disease. Dekker et al.’s third proposal was that 
development of PE due to a single recessive gene or a dominant gene with incomplete  
penetrance (19). 
 
Researchers looked at paternal aspects in triggering disease, due to the hypothesis that PE 
was a result of the maternal immune system rejecting a genetically foreign foetus. This 
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theory was introduced after recognising risk factors to PE in the demographics. It was found 
that PE appeared more likely to occur in first pregnancies, multiparous women that have 
changed partner, and in oocyte donation and intracytoplasmic sperm injection, suggesting 
a problem of primipaternity rather than primigravidity. However, evidence for this was 
inconclusive because trophoblasts do not express traditionally strong transplantation 
antigens like HLA-A, -B, or -D. Instead, invasive cytotrophoblasts that infiltrate maternal 
territory during placentation express a unique combination of HLAs, namely HLA-C, -E, 
and -G. Of these, only HLA-C is polymorphic for paternal alloantigens (55).  
 
However, modest evidence of a genetic interaction in PE existed, and in 2002 a review of 
the current position of genetics in PE research acknowledged the following key findings 
(56). In mouse models it was found that mice deficient of eNOS, or with an overexpression 
of angiotensinogen (AGT) had higher blood pressure in pregnancy but did not exhibit renal 
dysfunction, liver dysfunction, or haemolysis also characteristic of PE. In another mouse 
study, female mice with human angiotensinogen (hANG) and male mice with human renin 
gene (hRN) resulted in a severe PE-like syndrome. It was suggested these findings showed 
human renin, produced by the paternal gene in the placenta, shed into the maternal mouse’s 
circulatory system and could act on the human angiotensinogen, leading to progressively 
increasing hypertension with associating proteinuria (44).  
 
Alongside this, hereditary patterns of PE have long been strongly observed. A “maternal-
gene model” was floated when a case-study in 1968 detailing a well-recorded family history 
of 426 pregnancies demonstrated possible heredity of PE. The incidence of PE, described 
at the time as ‘toxaemia’, during first pregnancies was 26% in daughters, 25% in 
granddaughters and 8% in daughters-in-law (57). More case-studies derived from reliably 
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reported data on pregnancies emerged also supporting the “maternal-gene model” and 
ultimately in 1995 Arngrı́msson et al. confirmed the model through four tested models of 
inheritance (58). They concluded based on the available data, that a major maternal 
dominant gene must exist, with reduced penetrance or multi factorial inheritance. In 1998, 
maternal and paternal responsibility for the disease were concurrently reviewed in a 
population based study. When examining 61,186 pairs of mothers born to the same parents, 
the relative risk of a mother developing PE if her sister had also had PE was 2.2 (95% CI 
1.9–2.5) (59). The relative risk for PE while pregnant by a man who had previously fathered 
a pre-eclamptic pregnancy in another woman was 1.8 (95% CI 1.2–2.9). And, if a woman 
had a half-sister who had PE with whom she shared the same mother, this risk was 1.6 (95% 
CI 0.9–2.6), while sharing the same father the risk was 1.8 (95% CI 1.01–2.9) (59). This 
evidence was also used to exclude the possibility of a mitochondrial DNA genetic model as 
the relative risk among same mother siblings would be much more significant and not less 
than that of same father siblings. Come the early 2000’s where maternal, paternal and 
mitochondrial gene origins had been well studied, researchers next looked at other means 
to explain the disease.  
 
While research into the genetic basis of disease was increasingly yielding of results and 
important to understanding many diseases at the time, the technology for direct treatment 
of genetic disease was not soon available and researchers often found only incomplete 
penetrance of phenotypes leading to marginally significant results.  
 
A review of the current literature by Oudejans et al. in 2008 found that while it seemed PE 
and related syndromes had evidenced strong genetic links, the links were not consistent 
across populations or demographics (60). However, they also state that while disease is 
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often caused by immunological, vascular, metabolic, or traumatic disturbances, all but the 
latter will have some genetic underpinning. Another clear statement is that PE is caused by 
the placenta. Where there is no placenta, there is no disease, and even in cases of postpartum 
PE it is believed retained products of conception prolong the illness (61). With what we 
know about the unique functions of the placenta, it is likely that it controls maternal 
pathophysiology either by secreting active biologicals or by inducing an immunological 
response. Since most pregnancies do not result in PE, it is likely that the placenta is afflicted 
by its own pathology in order to cause this illness.  
 
The placenta, in its pathological state, is known to secrete a number of biomarkers 
aberrantly when compared to that recorded in its normal state (Table 4). Fluxuations in 
expressed biomarkers as associated with disease profiles are often the result of differences 
between tissues in a normal or pathological state. These differences are derived from 
inherited traits, or induced by biological agents (such as medications) or by pathogens. As 
the heritability of PE has been identified as a weak link and medications are not consistently 
found given to these patients, it begs the question; Have we yet to discover the genetic key 
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1.2.4.3 Inflammatory/Pathogen-induced disease:  
While some of the research prior to the late 1990’s had eluded to the presence of an 
inflammatory element in PE, the research mainly focused on the primary and most often 
present symptom of hypertension as a cause of systemic inflammation, however later 
research focused on hypertension as a symptom of inflammatory processes. Dekker et al.’s 
final proposal was that immune maladaptation caused decidual leukocyte resistance to 
trophoblasts during spiral artery remodelling. He believed this lead to endothelial cell 
dysfunction mediated by an increased decidual release of cytokines, proteolytic enzymes 
and free radical species (19).  
 
A 1999 review by Redman et al. included recent evidence from their work to suggest that 
endothelial dysfunction was part of a more generalized intravascular inflammatory reaction 
(73). Perhaps most forthcoming for the time was the notion that such an inflammatory 
response is already well developed in normal pregnancies and the differences between 
normal and pre-eclamptic pregnancies were much less pronounced that originally noted. In 
fact, this team made strong claims that PE was at the extreme end of normal variation and 
adaptation of the maternal body to pregnancy, and concluded that no specific cause for the 
disorder would be found, with an aside that poor placentation was a powerful predisposing 
factor. They state, “We predict that a single PE gene will not be found, nor will either a 
single specific predictive test or single preventive effective measure be devised.” (73)  
 
In 2005, Redman again reviewed recent evidence alongside the results of his own work. In 
his later review, he attributed more of the disease to immunological origins, citing new work 
suggesting trophoblast signalling to decidual immune cells is weak and fails to stimulate 
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collaboration, which is essential in early placentation (74–76). Decidual immune cells, or 
uterine Natural Killer (uNK) cells, have a differing function to other natural killer cells of 
the body. They are more likely to express cytokines than display cytolytic activity, and 
express receptors for the specific HLA combinations (HLA-C & HLA-E) seen on invasive 
cytotrophoblasts. Also important to immune regulation of uNK cells, is the KIR complex. 
Of the two HLA-C haplotypes, KIR binds more strongly to C2 than C1. KIR haplotypes 
also form two groups: A group codes mainly for inhibitory KIR, and B group having 
additional genes for stimulating NK cells (75). Hiby et al. found PE was significantly more 
prevalent in women who are homozygous for the inhibitory A haplotypes (AA) than in 
women homozygous for the stimulator B genes (BB). The effect is strongest if the foetus is 
homozygous for the HLA-C2 haplotype (OR 2.38, p=0.0001) (75). Redman concluded 
placentation is better and PE less common if the trophoblast strongly simulates uNK cells 
(74). However, this activation had not been confirmed in vitro.  
 
Redman also referred to his previous statements that pregnancy at baseline is pro-
inflammatory but in this review included reference to how the syncytiotrophoblast releases 
trophoblast and nuclei debris into the maternal circulation (73,74). They described how, in 
essence, this debris is also immunogenic and could be a source of increasing maternal 
systemic inflammation. His hypothesis was, that when the placenta suffers oxidative stress, 
likely as a result of poor placentation, the consequent tissue damage and necrosis could lead 
to further dispelled trophoblastic debris signalling the development of PE. Later he was able 




1.3 Human papillomavirus  
Human papillomavirus (HPV) is a non-enveloped DNA virus that infects epithelial cells. It 
is the most common sexually transmitted viral infection in the lower reproductive tract of 
sexually active women, predicted to infect up to 80% of women at some point of their 
reproductive life (77). HPV is known to infect the cervical epithelium by first making 
contact with the mucosa through a sexual encounter. The virus then infects basal epithelial 
cells of the squamous-columnar junction of the cervix. Until recently, it has been believed 
that the virus makes its entry into the basal epithelial cells through micro-wounds or micro-
abrasions however, early age first sexual debut, coarse sex and other sexually transmitted 
infections (STI) also promote virus entry and infection (78,79).  
 
1.3.1 Mechanisms of HPV 
Viral entry into the cell is mediated by Heparan sulfate proteoglycans (HSPG) found in the 
extracellular matrix (ECM) on the cell surface. These are thought to be the initial receptors 
of HPV virus-like particles. Initial attachment of HSPG moieties to the L1 portion of HPV 
facilitates the conformational change of L2 which is subsequently cleaved by furin on the 
cell surface at a consensus cleavage site that is conserved among all papillomaviruses (80). 
After a successfully binding to the receptor, the virus is internalized into the cell by clathrin 
or caveolae-mediated endocytosis (81). 
 
Once HPV has entered the cell, it is able to enter into the nucleus through nuclear envelope 
breaks instead of nuclear pore from there, it localizes the ND10 bodies inside the nucleus 
(82–84). HPV is a low copy number virus (10–200 copy number/cell) during the initial 
amplification and establishment of infection. Later as the proliferating cells (harbouring 
HPV genomes) undergo transition through differentiation, the mode of viral genome 
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replication switches to support productive viral genome amplification as shown with 
increased levels of the E1 and E2 replication proteins (85). In the terminally differentiated 
layer of epithelium L1 and L2 capsid protein genes are expressed and viral particles are 
assembled. The virions are sloughed off with the dead squamous cells of the host epithelium 
for further transmission. 
 
1.3.2 High risk vs Low Risk HPV and pathways to oncogenesis 
HPV is typed into two main categories: low risk and high risk HPV. High risk HPV’s are 
characterised by the presence of E6 and E7 oncogenic regions within the HPV viral genome 
(86). High risk HPV have been shown in in vitro, longitudinal and pathological studies to 
show persistence in infection and are significantly associated with cancerous lesions of the 
cervix via the mechanism of integration into the human genome and by inhibiting the DNA 
Damage Response (DDR) pathways (87,88). High risk HPV is able to do this by supressing 
two important stages of cell growth and function. HPV E6 protein contains two zinc finger-
like domains and uses these to bind to the tumour suppressor protein gene 53 (p53). p53 
normally controls G1/S and G2/M checkpoints and regulates pathways that lead to apoptosis 
(89–91). High risk HPV E6 also disrupts cell to cell signalling and adhesion via its PDZ 
domains, and upregulates telomerase activity (89,92). Similarly, HPV E7 binds to the 
retinoblastoma gene (Rb) sufficiently altering its function in a way that is transformative, 
predisposing the cell to mutations. In normal circumstances Rb suppresses tumour growth 
by inhibiting progression through the cell cycle at the G1 and S phase until it is appropriately 
inhibited by phosphorylation (93). When Rb is mutated or phosphorylated inappropriately, 
there is rapid movement through the cell cycle without the appropriate controls and the cell 
is marked for apoptosis (94,95). HPV E7 has also been associated with the overexpression 
of the cyclin-dependent kinase inhibitor p16INK4a (p16), which is normally a tumour 
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suppressor protein that prevents the phosphorylation of Rb. When HPV E7 mutates Rb, p16 
is unable to bind to it, subsequently it accumulates in tissues and has previously been used 
as a biomarker for detecting HPV infection (96–98). Both genes inhibited by HPV E6 and 
E7 play a role in preventing over-proliferation of cells and the development of cancer 
(99,100). Because most DNA damage recovery and check-pointing occurs in the G2 phase, 
HPV infected keratinocytes become over-proliferative. They are damaged but continue to 
divide, creating cancerous lesions that do not easily proceed to apoptosis (101–103). 
 
Low risk HPV is named ‘low risk’ based on its association to cancer, specifically cervical, 
and refers to the types of HPV that are least commonly found in cancerous lesions. Some 
of these types still contain variations of E6 and E7 but have been found to have a lower 
affinity for p53 and Rb (104,105). Consequently, it is likely that oncogenesis occurs most 
often in the presence of high risk infections but low risk infections still cause pathologies, 
such as condyloma acuminatum (genital warts), immunosuppression, poor skin healing and 
presence of a distinctly different vaginal microbiota than controls (106–108).  
                                                                                        
As keratinocytes are an epithelial cell, and mucosal surfaces exist throughout the body, 
HPV has also been found in squamous cell tumours of the mouth and esophagus, but has 
also been recently discovered in tumours such as glioblastoma multiforme (109) and various 
forms of breast tumours (110). Vidone et al. speculates that the virus may be a concurrent 
cause of gliomagenesis, providing the additional genetic hits likely required for HPV-
related tumorigenesis and leading to the activation of oncogenes (109). As well as this, 
though HPV is considered to be an exclusive epitheliotropic pathogen, it’s virions have 
been detected bound to cells from several tissues and species (111) and HSPG, by which 
HPV binds to for entry into the cell, are also found to be expressed in astrocytes (112). 
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Additionally, investigators examining HPV status in relation to esophageal 
adenocarcinomas also include HPV’s known ability to downregulate miR-125b, where 
lower levels of the microRNA are associated with tumorigenesis through the Wnt/β-catenin 
signalling pathway (113). Detection of HPV can be inconsistent in cancer study cohorts, 
with esophageal cohort studies exhibiting positive results in 13-35% of cases and as few as 
no cases in a study of 233 cases (114). 
 
More recently, HPV and disease associations have been found outside of cancer studies and 
have become a focus in pregnancy and cardiovascular disease (CVD). Huang et al. found a 
twofold increase in pre-term birth among women who had previously positive cervical HPV 
swabs (pooled OR 2.12, 95% CI [1.51–2.98]) (115). Two longitudinal studies showed 
between a OR 1.25-2.3 (95% CI, [1.03-1.52], [1.27-4.16]) of developing CVD after 
contracting HPV, with the risk increasing to 2.86 (95% CI [1.43–5.70]) when adjusted for 
high-risk HPV infection (116,117).  
 
1.3.3 HPV in Reproductive Pathology 
HPV is predominantly known for its oncogenic predisposition for the development of 
cervical cancer (78,87,118–122). Outside this, it was first investigated perinatally due to its 
effects as oral HPV infection of the neonate. Multiple studies found a statistically significant 
rate of infection the mother and child however some cases arose where the mother was HPV 
negative but the child was positive. When researchers looked at presence of the virus in the 
placenta and umbilical cord to correlate to oral HPV infection of the neonate, their results 
suggested placental transfer was a more likely mechanism than infection while in the birth 
canal during vaginal birth (123–125).  
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Next, with what is known about HPV’s oncogenic properties, researchers looked for the 
virus in endometrial cancer. Review of multiple studies by Olesen et al. reveals a wide 
range of rates of infection in endometrial tumours, with some reporting as high as 61%, but 
after analysis found HPV to be present in approximately 10% of all endometrial cancers 
(126–130). One study of 25 endometrial tumours found no difference in HPV infected 
tumour cells to those neighbouring it whom were not infected, suggesting that HPV is more 
of a ‘bystander’ in this disease than contributing to its pathology (126).  
 
Studies of placental trophoblasts infected in vitro with HPV types 16 and 18 revealed 
trophoblasts do not function as efficiently in producing adhesins to the endometrium (131–
134). Likewise, endometrial cells (that differentiate into decidua in pregnancy) also fail to 
exhibit adhesins (131). In 2008, Gomez et al. published a study where trophoblasts 
transfected with the HPV type 16 genome had rates of apoptosis that were 3-6 fold greater 
than in non-transfected cells or cells transfected with an empty plasmid (136). Invasion of 
transfected cells through extracellular matrices was also 25–58% lower than that of the 
controls. In addition to these in vitro findings, cells from three cohorts of human 
pregnancies were collected; severe PE, spontaneous pre-term deliveries and controls. 
Identification of HPV DNA in extravillous regions of placental samples from cases of 
severe pre-eclampsia was not significantly different from that of controls (8/48 versus 6/30; 
p=0.71). HPV DNA was detected more frequently in the extravillous trophoblast region of 
placentas from spontaneous cases of pre-term delivery (15/30) than from controls (6/30; 
p=0.03) with the majority of these being deliveries of less than 34 weeks gestation (136). 
Another study looked at placental tissue from spontaneous miscarriages versus elective first 
trimester termination (planned surgical TOP). It found 60% of placenta from spontaneous 
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miscarriages were positive for HPV E6/E7 DNA sequences. In comparison, only 20% 
elective samples were positive (137). 
 
More recently, a cohort of term placentae with anatomical and molecular pathologies was 
found to have a statistically significant quantity of samples with concurrent HPV 
infection. In the Slatter et al. study, investigators examined the cohort using established 
immunohistochemistry techniques, for the HPV L1 viral capsid protein which is indicative 
of infection of the placenta by HPV. 253/339 (75%) of the placentae were positive for the 
HPV L1 capsid protein, and of these 197 were positive (78%) and 56 were negative (22%) 
for HPV high-risk DNA. In addition, in the 232 placentae from pregnancies with 
complications (PE, GD, IUGR) 83% (192/232) were HPV positive compared with 57% 
(61/107) of placentae from uncomplicated pregnancies. In the decidua of positive placenta, 
the tissue was unremarkable on H&E staining however the L1 was mostly present in the 
cytoplasm of the cell and dual staining for gamma H2AX and p53 IHC revealed DNA 
damage/repair responses in the locations positive for HPV. In a smaller subset of HPV 
positive placentae (n=35), patchy areas with variable numbers of infiltrating villous 
lymphocytes, consistent with lymphohistiocytic villitis (LHV). A further subset (n=55) also 
demonstrated sclerosing villitis (SV), a pathology associated with inflammatory resolution 
following LHV. When the HPV-positive placenta were characterised by their clinical 
outcomes, it was found that HPV was present in 84% (74/88) pre–term, 76% (55/72) of the 
FGR, 81% (13/16) of the intrauterine foetal death, 92% (23/25) of acute chorioamnionitis, 
95% (42/44) of diabetes, and 100% PE (20/20) cases (2).  
 
In retrospective clinical cohort studies, rates of PTB and PE were examined to determine if 
these obstetric risks were increased in women who were HPV+. In one study PTB and PE 
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were not found to be statistically significantly higher in women who were HPV+ in a 
previous cervical cancer screening than women who were HPV- (138). However, in a study 
looking at HR-HPV positive women the rate of PTB and PE were found to be statistically 
significantly higher, with an adjusted OR of developing PE of 2.18 (1.31-3.65, 95%CI) 
compared to controls (139). Lastly a retrospective study of PTB also found PPROM to be 
associated with HPV infection but not PTB exclusively (140).  
 
1.4 Possible mechanism for HPV induced Hypertensive Disorders of Pregnancy 
In the study by You et al. (2002), introduction of HPV E6/E7 into trophoblasts resulted in 
defective adhesion to endometrial cells suggesting E6 and E7 expression would result in 
reduced infiltration of extravillous trophoblasts into the decidua basalis early in pregnancy, 
as per the finding of anatomical pathologists (73,141,142). It was hypothesised that this 
triggered oxidative signalling, due to the poor perfusion of foetal vessels, and this lead to 
immune activation of decidual macrophages (143). This in turn led to the maternal disease 
responses of hypertension and inflammatory transaminase activity (144). Borzychowski et 
al. found in a review of studies of inflammatory markers in pregnancy, in both histological 
and blood based quantification, that the degree of inflammation was linearly correlated 
along a continuum of IUGR, PE and foetal death (144). Their conclusion was that the failure 
to develop an adequate blood supply to the placenta led to placental oxidative stress, excess 
release of placental factors into the maternal circulation, such as syncytiotrophoblast debris 
and vascular endothelial growth factor (VEGF), which triggered an inflammatory response 
and endothelial dysfunction (144). However, they also note that PE can develop in the 
presence of the anatomically normal placenta belonging to women that are susceptible to 
systemic inflammation, such as with chronic CVD or diabetes. Hence investigating the 
mechanism that causes failed spiral artery remodelling or perhaps a mechanism that 
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promotes an immune response without causing these damaging anatomical pathologies is 
vital to understanding exactly how and why PE arises. 
 
Perhaps the most notable study of late in understanding the mechanisms that link HPV 
infection with PE is the studies of Gomez et al. They isolated human Endometrial Stromal 
Cells (hESC’s) from women who had a previous pregnancy with severe PE and compared 
these to cells from women with previous uncomplicated pregnancies. The control cells 
underwent growth and organisation, in response to biological messenger signalling, 
consistent with changing from a fibroblast to a decidual phenotype. Control cells also 
exhibited a dramatic increase in secretion of PRL and IGFBP1. hESC’s from women with 
prior severe PE failed to undergo these changes and did not greatly increased their secretion 
of PRL and IGFBP1, suggesting a pathology inherent to these cells (145). If this work in 
vitro is consistent with true in vivo function, failed decidualisation as predicted based on in 
vitro studies by HPV infection may have a role to play in early malplacentation.  
 
Global transcriptional profiling was undertaken which found that when comparing the 
transcriptomes of both groups, hESC’s from a PE setting (that were able to undergo 
decidualisation) had 129 differently expressed genes (DEG’s). Specifically, 15 genes were 
up-regulated during normal hESC decidualization and down-regulated during 
decidualization of hESC from women with previous PE, most of which were signalling 
molecules, however IGFBP1 and PRL were significantly downregulated (145). Gomez et 
al. also references the work of Rabaglino et al. who analysed gene expression of chorionic 
villous samples that were obtained near the end of the first trimester from pregnancies in 
which the women went on to develop severe PE. In both studies, it was found that alterations 
of gene expression were related to decidual genes (IGFBP1 & PRL), rather than 
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cytotrophoblast, and differential expression of immune cell genes identifying the presence 
of  maternal leukocytes within the uterine lining (145,146). Further to this, Gomez et al. 
identified that NK cell receptors and T-cell receptors were misexpressed in the context of 
PE (145). Immune cell receptors, specifically KIR have been observed extensively in the 
context of PE (55,75,147,148) but abnormalities in expression have also been observed in 
the context of high risk-HPV (149–151). Rizzo et al. were able to identify a strong 
correlation between the presence of the high inhibitory HLA-C/KIR variants and neoplastic 
lesion development in the context of high risk HPV infection (151). The increase in 
inhibitory HLA-C/KIR pair frequencies in high risk HPV infected patients suggests the 
virus directly inhibits NK cells, allowing the virus to sustain transformations in its target 
cell (151). As NK cells are important in the process of vascular remodelling (31), it is 
possible that the perceived ability of HPV to inhibit NK cells could also be detrimental to 
placentation at early stages.         
 
Another key component in understanding if HPV is causative towards pregnancy 
complication is whether E6 and E7 are expressed in pregnancy. The oncogenic ability of 
high risk HPV depends on E6/E7 expression (152). Most studies investigating HPV in 
reproductive pathologies tested for the presence of HPV DNA (82,99,134,136,153–158). 
Using immunohistochemistry to detect E6 and E7 is often associated with many false 
positive results so providing evidence for transcriptional activation of E6 and E7 is regarded 
as the gold standard for the presence of clinically relevant HPV (159). Studies of whether 
E6/E7 is expressed in the placenta is limited to a single study, which found no evidence for 
E6/E7 from HPV 16 using quantitative real time PCR (160). 
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We hypothesise that presence of HPV E6/E7 precipitates the development of HDP, 
specifically PE, by inhibiting the decidualisation, trophoblastic invasion and spiral artery 
remodelling necessary to have a placenta that functions appropriately all the way to term. 
It may then be that IUGR, oxidative signalling and maternal immune activation are results 
of an anatomically insufficient placenta. Maternal immune activation against the placenta 
mounts as the placenta grows or becomes compromised and causes chronic inflammation 
leading to hypertension, acute phase protein production and coagulopathies as seen in the 
clinical progression of HDP. The maternal immune system may become aware of either or 
both fetal DNA and HPV in the placenta through subsequent breakdown or dysfunction of 
its immune barriers. There is localised immunosuppression in the uterus during pregnancy 
(161), and HPV has been observed to reactivate at the site of previous infection in 
immunosuppressed individuals (107,108). Therefore, HPV could be causative in HDP or a 




1.5 The role of epigenetics in Hypertensive Disorders of Pregnancy 
Epigenetics is the study of chemical modifications to the genetic code that can alter gene 
expression, rather than alteration of the genetic code itself. Epigenetic studies can reveal a 
number of clues about the structure, and therefore function, of the genetic material in an 
individual. Each person’s epigenetic make-up is as unique as their genetic make-up, and 
epigenetic marks can change throughout one’s life in response to environmental cues (162). 
Chemical modifications to the genome can lead to varied levels of expression of target 
genes, many of which enable the body to maintain homeostasis through signalling and 
protein production. One of the most well studied epigenetic modifications is DNA 
methylation - the addition of a methyl group to a cytosine residue in the DNA sequence. 
Lower levels of DNA methylation are associated with greater availability of genes for 
expression, which can lead to genome instability (162,163).  
 
Some key attributes of HDP are: 1) they can vary in severity in each pregnancy or not exist 
at all, 2) they can arise in subsequent pregnancies for a women whom has had previously 
healthy pregnancies with a different partner, and 3) antihypertensive medications may lower 
blood pressure as in other similar cardiovascular syndromes outside of pregnancy but 
overall the progression of disease is not altered by medications. Therefore, when the 
presence or absence of a gene mutation could not explain the disease, investigators turned 
to epigenetic causes. Such changes might influence the expression of genes, and explain the 
existence and variability of the certain diseases.  
 
One major challenge of research into genomics and epigenomics of the placenta is that the 
heterogeneity in the placental cell population can dilute the specificity of results. 
Previously, genome-wide methylation studies in the human placenta reported a 22% 
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reduction in methylation compared to that of neutrophils (a representative somatic tissue) 
(164). This was mitigated by Gamage et al. who isolated trophoblasts from first trimester 
placenta and then sequenced the CpG sites to examine the methylome of placental 
trophoblasts and whether that influences abnormal placentation. They found that between 
human trophectoderm and inner cell mass samples, they did not have significantly different 
levels of global methylation. They suggested that differences in global CpG methylation 
between trophoblasts and somatic cells are much smaller than previously reported and 
hypothesised that different patterns of CpG methylation contribute to successful 
placental/trophoblast function (5). In another experiment, they went further to isolate the 
distinct populations of trophoblasts; EVT, CTB and side populations of trophoblasts. EVT, 
the population responsible for invading the decidua and remodelling uterine spiral arteries, 
were found to be hypermethylated in 95% of CpG sites compared to CTB, and 96% of sites 
were hypermethylated in comparison to side population cytotrophoblasts (4). This 
widespread silencing of genes known to regulate growth and differentiation is theorised to 
contribute to the invasive nature of EVT.  
 
At the time when the Braithwaite-Slatter Lab were looking into HPV in relation to PE, the 
Macaulay Lab (Department of Pathology, University of Otago), was undertaking research 
that aimed to determine epigenetic differences between pregnancies complicated by HDP, 
and specifically PE, and controls. We decided to incorporate this research into this project.  
 
The Macaulay Lab had previously conducted genome-wide methylation discovery 
experiments using Reduced Representation Bisulfite Sequencing (RRBS) and Infinium® 
MethylationEPIC BeadChip arrays (850K) to identify differential methylation in PE. To 
compliment this work, they also performed a large-scale analysis of publicly available 450K 
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methylation data from seven independent PE cohorts. Their candidate differentially-
methylated genes identified were then quantified by using deep-targeted methylation 
sequencing (MiSeq, Illumina, USA) to validate differential methylation in two PE focused 
cohorts (the OPuS and Japanese cohorts, to be introduced in Section 3.1). This work was 
performed by Suzan Almomani (PhD student), Ryan Powell (Assistant Research Fellow), 
and Dr Abdul Alsaleh (former PhD student, Morrison lab) in the Department of Pathology, 
University of Otago, Dunedin, NZ. The 850K work was performed in collaboration with 
Prof Greg Jones (Department of Surgical Sciences, University of Otago).  
 
Of the significant differentially-methylated genes identified, we selected two; NOTCH2 and 
CMIP, based on their potential associations with pregnancy complications as per the current 
literature and ease of access to research-grade investigative probes.  
 
1.5.1 Target Gene One: NOTCH2 
NOTCH2 is a well-known gene in relation to PE, and the only of our target genes to have 
current, directly related research on its regulation in PE. Members of this Type 1 
transmembrane protein family share structural characteristics including an extracellular 
domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an 
intracellular domain consisting of multiple, different domain types (165). Notch family 
members play a role in a variety of developmental processes by controlling cell fate 
decisions. The Notch signalling network is an evolutionarily conserved intercellular 
signalling pathway which regulates interactions between physically adjacent cells (165). In 
regards to PE, NOTCH2 was found by Zhao et al. in 2015,  to be expressed in the villous 
trophoblast. They compared up and down regulation of the gene, and its related gene 
NOTCH3, with cell proliferation and apoptosis. They found when both genes were 
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upregulated, more cell proliferation took place, and downregulation of NOTCH2 genes lead 
to increased apoptosis (166). Zhao, later looking exclusively at NOTCH2, also found in cell 
lines that when NOTCH2 was downregulated in BeWo cells, while the proliferation was 
dramatically promoted, the migration and invasion were both significantly inhibited (167). 
In another experiment, reduced NOTCH2 expression was correlated with Severe Early 
Onset PE (Severe-EOPE) (168). These observations fit with the theory that PE is caused by 
poor placentation in the very early stages of pregnancy. 
 
1.5.2 Target Gene Two: CMIP 
CMIP, or C-maf inducing protein, induces signalling of production of IL-10 & IL-21 by 
T1reg T cells by binding with AhR and then IL-10 & IL-21 promotor regions. The 
production of these cytokines have downstream effects by down-regulating T-cell 
proliferation and cytokine production (169,170). While the immune system in pregnancy is 
often dampened, by favouring Th2 responses (161), increased inflammatory signalling in 










2. Aims and objectives 
HPV infects the wider reproductive system with types that express E6/E7 causing abnormal 
cell function, predisposing the development of HDP. Greater evidence for a role of HPV in 
placental dysfunction requires us to identify that E6/E7 is expressed in placentas from 
pregnancies complicated by HDP. In situ based analyses offer advantages to investigating 
placental function as gene expression differences can be investigated in a spatial context. 
These can be used to determine if and where HPV E6/E7 is expressed in the placenta. In 
situ based analyses can also be applied to investigate if methylation differences associated 
with PE result in gene expression differences in the placenta. 
 
We wish to provide better evidence that HPV is active in HDP to expand upon the previous 
findings of increased HPV DNA in HDP demonstrated by Slatter et al. (2), and will test this 
in a cohort of placentas from control and HDP complicated pregnancies from Japan gifted 
to us by Dr Ryuji Fukuzawa (Department of Pathology, University of Otago, Dunedin, New 
Zealand and Department of Pathology, School of Medicine, International University of 
Health and Welfare, Narita, Japan). Furthermore, we would like to investigate methylation 
differences in our selected target genes by visualising the differences in RNA expression, 
using RNAscope®, between the cases and controls.  
 
Hypothesis: Human papillomavirus infection of the developing placenta leads to 
pathogenetic changes that contribute to the development of hypertensive disorders of 
pregnancy and will therefore be found in a higher proportion of affected placentae.    
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For this project, we had two main objectives:  
 
Objective 1: Identify using RNAscope® the presence of high and low risk HPV E6/E7 
RNA in a cohort of cases complicated by hypertensive disorders of pregnancy (HDP).  
 
Objective 2:  Investigate the use of RNAScope® as an in situ technique for quantifying the 
expression of target genes in the presence of disease. Identify if this could be used to 
determine a relationship with DNA methylation data, or inform its efficiency in a multi-
cellular tissue. 
 
Evidence of expression of HPV E6/E7 in the placenta would add to the growing body of 
information identifying an association between HPV and HDP. It would also show that 
HPV is active in the placenta during pregnancy. With these findings we hope to support 
future research into the mechanisms of HPV in reproductive pathologies with the ultimate 
aim of reducing the case incidence of HDP altogether. Collectively these findings would 










3.1 Tissue Collection and Ethical Approval  
3.1.1 Ethics 
Multiple sample cohorts were used for this research. The Japanese samples supplied by Dr 
Ryuji Fukuzawa and his team were collected in Japan under the Tokyo Metropolitan Tama 
General Medical Center Ethical Approval #9. Otago Placental Collection Study (OPuS) 
samples were previously collected under Ethics Consent from the University of Otago, 
Dunedin, NZ (LRS09/09/038). Gynaecological specimens (endometrium) were consented 
for research under Ethics Consent from the New Zealand Health and Disabilities Lower 
Regional South and Multiregional Ethics Committees. 
 
Samples used for the optimisation of the RNAscope® assay had previously been HPV typed 
by EUROArray HPV testing (Euroimmune) to be HPV 18 and 16 positive (OPUS199). 
Samples used in for the optimisation of the Immunohistochemistry assay (Gynae 065) were 
selected for being appropriate control tissues for the CMIP antibody (170), as the CMIP 
gene is known to function in glandular tissues, and was recommended as per the suppliers 
guidelines (171). 
 
3.1.2 Collection of samples 
Samples from the OPuS cohort (placental) and from the gynaecological specimens 
collection (endometrium) were taken from in laboratory storage and used for optimisation 
only. 
 
Samples of FFPE transmural placental slices for our main study were sent by Dr Ryuji 
Fukuzawa from his laboratory in Japan to our laboratory in New Zealand in January 2019. 
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These samples were collected in 2017 from patients at Tokyo Metropolitan Tama General 
Medical Center. Sent with the samples was a spreadsheet of associated clinical data, some 
information from this was missing. The samples were grouped and named by Dr 
Fukuzawa’s team originally according to the Japanese Society for the Study of 
Hypertension in Pregnancy (JSSHP) guidelines. They were originally named PET 
(Preeclampsia), Non-PIH (Non-pregnancy induced hypertension related pathologic) or 
CTL (Control). We regrouped and named the samples according to NZ guidelines on HDP 
to meet the clinical criteria where the information to do so was available. There were 16 
case samples pertaining to patients clinically diagnosed with a HDP (HDP group), 6 case 
samples pertaining to patients who were not clinically diagnosed with HDP but had other 
pregnancy-related pathologies (Non-HDP pathologic group), and 15 case samples 
pertaining to patients with no pathological diagnosis in pregnancy (Control group). Our 
rationale for this was to better clarify the samples relevant to our study in order to be 
inclusive of the conditions we set out to cover. 37 case samples in total were sent along with 
their corresponding clinical data (Appendix 7.3).  
 
Clinical data associated to the cases contained in a spreadsheet included; Maternal age, 
mode of delivery, APGAR scores at delivery (at 1, 5, & 10 minutes), Smoking status, BMI, 
Gravidy/Parity, Number of previous miscarriages, Baby’s sex, Gestation (weeks & days), 
Foetal Birth Weight and standard deviations according to growth charts, Maternal Blood 
Pressure during delivery, Liver enzymes, Platelet count, Types/Severity of PE diagnosis (if 





3.2 Sequencing Methylation Data  
The target genes for this project were discovered by performing genome-wide methylation 
analysis methods. Reduced Representation Bisulfite Sequencing (RRBS) was first 
performed on 9 cases (of PE) and 6 controls from the OPuS cohort. This technique uses, a 
methylation-insensitive restriction enzyme to slice DNA into fragments.  Purified fragments 
contain the majority of promoter sequences and CpG islands which are then bisulfite 
converted, which deaminates unmethylated cytosine into a uracil. The DNA fragments are 
then sequenced and the sequences realigned into a genome (172). The Infinium® 
MethylationEPIC BeadChip (Illumina’s 850K assay) was next used to examine 23 cases 
and 15 controls from the Japanese HDP cohort. This assay interrogates the methylation 
status of ~850,000 CpG sites by using individual probes that correspond to methylated and 
unmethylated CpG sites. Single base extension is used to determine whether the site is 
methylated or unmethylated (173).  
 
Candidate genes showing the largest and most significant differences in methylation were 
analysed using deep-targeted sequencing to validate their results. Two differentially 
methylated genes were selected for use in this study based on their potential associations 
with pregnancy complications and ease of access to research-grade investigative probes 
(NOTCH2 and CMIP). NOTCH2 displayed a 36% reduction in DNA methylation in PE, 
and this differential methylation was validated in the Japanese cohort. CMIP displayed a 
16% reduction in DNA methylation in PE, and this differential methylation was validated 




3.3 Preparing slides for testing 
Samples were received as formalin fixed paraffin embedded (FFPE) tissue. Sections for 
immunohistochemistry were cut at 4 μm and then baked at 60°C for one hour before use 
then stored until needed. Sections for RNAscope® were cut at 5 μm and left unbaked and 
stored, and then baked at 60°C for one hour before use. All slides were marked with the 
shortened sample code, date, and indication of what assay was performed. This was 
performed by Histology Unit Technical Staff at the Department of Pathology, University of 




3.4 RNAscope®  
The RNAscope® RNA in situ hybridisation Chromogenic assay (Advanced Cell 
Diagnostics, Newark, USA) is used to detect RNA in situ on FFPE tissue (174). In 
summary, this method is performed on tissue sections set onto microscope slides allowing 
the result to be both specific for the target and show its presence in relation to the 
surrounding anatomy and pathologies. Firstly, the tissue is treated to expose the RNA within 
the cells. A probe-containing solution with multiple Z probes is added to the tissue section. 
For each Z probe that binds to the RNA in the exposed tissue, at least two probes must bind 
side by side to create a double Z probe. This enhances specificity of the target, the specific 
RNA of interest, for amplification. A series of amplification steps allow detection of target 
RNA within the tissue section. With counterstaining, this staining can be detected under the 
microscope with positive labelling seen as brown or red (kit dependant) punctate staining.  
 
Microscope slides with 5 μm of tissue were baked immediately before use at 60°C for one 
hour. Following baking, slides were deparaffinised using two Xylene (ThermoFisher 
Scientific) washes for five minutes, followed by two 1-minute washes in 100% ethanol. 
Depending on the amount of blood and tissue on slides, five to eight drops of hydrogen 
peroxide solution (ACD) were placed on the slides for ten minutes at Rt and then briefly 
washed in dH2O. The slides were placed into the RNAscope® Target Retrieval Reagents 
solution (ACD) at 98-102°C for a duration of twenty minutes, above the suggested fifteen 
minutes for placental tissues but as per our optimisation of the assay. Slides were then 
washed in dH2O two times. A hydrophobic barrier was placed on each slide using the 
ImmEdgeTM Hydrophobic Barrier Pen (Vector Laboratory, Burlingame Ca, USA) and four 
drops of RNAscope® Protease Plus (ACD) were placed on each slide in a humidity 
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chamber (ACD). The chamber was then placed into the HybEZTM hybridization oven 
(ACD) for thirty minutes at 40°C. 
 
The following probes were used; Homo sapiens Ubiquitin C (UBC) mRNA (messenger 
RNA) positive control probe (ACD), Homo sapiens Cyclophilin B (PPIB) mRNA 
(messenger RNA) positive control probe (ACD), Dihydrodipicolinate reductase (DapB) 
negative control probe (ACD), HPV-HR18 probe towards E6/E7 of 18 high risk HPV types 
(16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) (ACD), LR-HPV-
HPVE6/E7  probe towards ten low risk HPV types (6, 11, 42, 43, 44, 54, 61, 70, 72 and 81) 
(ACD), Homo sapiens NOTCH2 probe (ACD).  
 
Following enzyme digestion and washing in dH2O, four drops of each probe (warmed to 
37°C before use) were placed on the slides (more added for larger tissue sections or those 
with lots of blood), and slides placed back in the humidity chamber of the hybridization 
oven for two hours at 40°C. Slides were then washed in 1x Wash Buffer (ACD) on a shaker 
for two minutes and the wash step repeated. A series of amplification steps (1-6, 
RNAscope® 2.5HD Assay-Brown) were then applied with incubation and washing steps 
performed according to the manufacturer’s instructions.  
 
For each amplification step four drops per slide of the corresponding amplification reagent 
were used and after each amplification the slides were washed in the Wash Buffer for two 
2-minute washes. After the sixth amplification and subsequent wash steps, DAB (ACD) 
was placed on the slides for ten minutes at Rt. DAB enhances the target signature by 
producing a precipitate that is insoluble in xylene and water. Excess DAB is washed off 
with tap water, and 3-5 drops of DAB enhancer (Leica Biosystems, Wetzlar, Germany) 
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added to the slides for ten minutes to enhance the signal (above the manufacturers 
recommendation but required in our assay to enhance the signal). Slides were washed in tap 
water and counterstained with Mayer’s haematoxylin (Amber Scientific, Midvale, 
Australia) by submerging for ten seconds, washed until water runs clear and dipped in 
Scott’s blue swiftly three times then dehydrated in 100% ethanol. Slides were coverslipped 
using DPX (Merck Group) as the mountant. 
 
Optimisation of all assays was performed by myself. Following this, the majority of the 
RNAscope assays were performed by Ashley Reily-Bell, Assistant Research Fellow, 
Department of Pathology, University of Otago, New Zealand. The analysis and 




3.5 Immunohistochemistry using CMIP Antibody  
Anti-CMIP antibody ab237049 (Abcam, Cambridge, UK), a rabbit monoclonal antibody, 
with human cross-reactivity was selected from a set of commercially available antibodies 
(171). Endometrium was selected as a high CMIP expressing tissue that was also easily 
available to us in the laboratory (170). FFPE 4μm endometrial tissue sections were placed 
into the Leica Bond RX Research autostainer (Leica Biosystems), and a protocol (ISH 
Protocol F) was applied with reagents (Enzymes 1 & 2, Bond Anti-Biotin Antibody, Bond 
Stringency Wash, Bond Polymer Refine Detection Kit, and Bond DAB enhancer) as 
recommended by the manufacturer. Modifications to the recommended protocol included a 
test with both Enzyme 1 and Enzyme 2 to see which would yield a better stain, a 3 hour 
antibody incubation period and adding signal enhancer. Slides were then removed, 
dehydrated, and mounted following a standard procedure of three 1-minute washes of 
absolute ethanol (ABS) (AnchorEthanol) and then three 1-minute washes of Xylene 
(ThermoFisher Scientific, Massachusetts, USA). Slides were then coverslipped with DPX 
Mountant (Merck Group, Darmstadt, Germany).  
 




3.6 Scoring and Interpretation of RNAscope®  
Completed slides were scanned and viewed in Aperio Imagescope (Leica Biosystem) at 
400x. ACD, the company that has commercialised RNAscope® Assay, recommend using 
a semi-quantitative scoring guideline to evaluate the staining results. They recommend 
scoring the number of dots per cell (Table 5), rather than the signal intensity, as the number 
of dots correlates to the number of RNA copy numbers, to which a probe has bound. An 
example scoring guideline given for HeLa cells is found on the website where the example 
expression level is 1-15 copies per cell (120,175).  
 
Table 5: Reference table for RNA Scoring guidelines. 
Score  
0 No staining or <1 dot/ 10 cells  
1 1-3 dots/cell 
2 4-9 dots/cell. None or very few dot clusters 
3 10-15 dots/cell and <10% dots are in clusters 
4 >15 dots/cell and >10% dots are in clusters 
 
 
Evidence of copy numbers for NOTCH2 were not found in any literature, as previously 
studies had compared directly between cohorts, thus we opted to maintain the same scoring 
and interpretation methods as above (for HPV) and compare directly between cohorts as 
well as compare expression levels of NOTCH2 to areas known to be infected with HPV. 
 
Visual analysis was undertaken by myself as a trained examiner and scored against the 
above criteria using only a numerical code name to record against (e.g. S16_01199). 
Analysis was also undertaken by two more trained and experienced examiners and any 
discrepancies re-examined and discussed as a group. All examiners were blinded to the 
clinical information of each case when undertaking the analysis.   
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3.7 Statistical Analyses 
c2 tests were used to compare differences between categorical measures and unpaired 
Student’s t-tests to compare between contiguous measures. Statistical significance was 






4.1 Experimental design and analysis 
At the beginning of optimising RNAScope®, we compared two positive control probes of 
PPIB (peptidyl-prolyl cis-trans isomerase B) and UBC (Ubiquitin C). UBC has been used 
as a standard probe for measuring RNA quality as UBC is found in many tissues and has 
been routinely used in the laboratory (176,177). PPIB has been described for use in 
placental tissue as a positive control as it is highly expressed across many cell types in the 
placenta (10-30 copies per cell) (177,178). When comparing separate slides of the same 
samples stained with either PPIB or UBC, PPIB had no or inconsistent staining across cell 
types compared to staining by UBC. UBC also had positive staining in almost all cells in 
the placenta. Based on this result PPIB was not found to be an improved positive control 
compared to UBC, so UBC was continued as the positive control (Figure 6).  
 
Each case was tested using a UBC (positive control) RNAscope® probe and those with poor 
RNA quality excluded. UBC is routinely used as a positive control to determine the RNA 
quality of samples in our lab. Slides processed with the UBC probe which were found to 
have poor or inconsistent staining were repeated to be sure of this result then excluded from 
progressing to processing with experimental probes (179). The HDP group contained 16 
placentas with 15 containing RNA with good or moderate quality for subsequent 
RNAscope® analyses. The placentas with good or moderate RNA included nine cases of 
PE, and six cases of another HDP. Five out of six cases from non-HDP pathologic group 
were of good or moderate RNA quality. Eleven out of fifteen cases in the control group had 
good or moderate RNA quality. This led to the final group sizes: HDP cases=15, non-HDP 





Figure 6: PPIB vs. UBC as a positive control probe for RNA quality in the placenta. 
A: PPIB positive control probe was not used as the staining was very low and therefore not accurate 
enough to determine RNA quality. B: Good quality of RNA hybridization from UBC positive control 
probe. This was selected as our positive control probe in order to determine if RNA quality was 









Figure 7: Examples of good, moderate and poor UBC probe (positive control) quality using 
RNAscope®. 
For this study only cases with good or moderate UBC quality were included in order to reduce the 
risk of false negative results. Left column: Good quality RNA visualised by large, consolidated areas 
of brown punctate staining intracellularly using UBC probe. Middle column: Moderate quality RNA 
visualised by dense brown punctate staining intracellularly using UBC probe. Right column: Poor 
quality RNA visualised by sparse brown punctate staining intracellularly using UBC probe. Shown 
at 400x magnification. 
 
50 µm
50 µm 50 µm 50 µm
50 µm 50 µm
50 µm50 µm50 µm
UBC: Good UBC: Moderate UBC: Poor
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4.2 High Risk HPV RNAscope®  
In the HDP group, high risk E6/E7 was identified in 40% of the cases (n=6/15). Of these, 
five of the cases were diagnosed with PE (55% of the PE cases in the HDP group). Four of 
the Non-HDP pathological cases (n=4/5) tested positive for high risk E6/E7 expression 
(80%). None of the control cases (n=11) tested positive for high risk E6/E7 expression (0%). 
Examples of positive HPV HR E6/E7 and DapB negative control staining are shown in 
Figures 8-11.  
 
All of all the positive cases in the HDP group (n=6/15) were positive in the decidua and 
chorionic villous regions. Of these, three cases had decidua with a score of 1 (50%), and 
three with a score of 2 (50%). Only one case had a score of 1 (17%) and five had a score of 
2 (83%), in the chorionic villous regions. Of the four positive Non-HDP pathologic cases, 
two were scored 1 (50%) and two scored 2 (50%) in the decidua. In the chorionic villous 
region, similarly two were scored 1 (50%) and two scored 2 (50%).  
 
High risk HPV E6/E7 was more likely expressed in the HDP group compared to the control 
group (Table 6). Using the χ2 test, the presence of high risk E6/E7 expression in the HDP 
cases (n=6/15) versus the control group (n=0/11) was found to be statistically significant 
with a p value of 0.0015 (z=3.177, df=1). The Non-HDP group was excluded from the 
statistical analysed due to the limited number of cases. 
 
Positive slides from these cases were also examined by a trained clinical anatomical 
pathologist signs of villitis, which has been observed in cases of poor placentation (2). Three 
of the high risk E6/E7 positive cases also had signs of villitis (n=3/5, 60%). While all of the 
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non-HDP pathologic cases (n=5) were from pregnancies complicated by IUGR, only one 

























































Figure 8: HPV E6/E7 expression in the decidua basalis of placentae from pregnancies affected 
with pre-eclampsia. 
Examples of HPV E6/E7 expression using an RNAscope® assay towards 18 high-risk HPV types in 
three cases and the negative control (DapB) for one case. Positive cells denoted by thick arrows. 
Top left: Brown punctate staining is visible indicating positive cells. Magnified insert clearly shows 
HPV E6/E7 positive cells. Bottom left: Negative control (DapB) shows no staining confirming a 
true result in the top left image. Top right: Brown punctate staining is visible indicating positive 











Figure 9: HPV E6/E7 expression in the chorionic villus of placentae from pregnancies affected 
with pre-eclampsia.  
Examples of HPV E6/E7 expression using an RNAscope® assay towards 18 high-risk HPV types in 
two cases. Positive cells denoted by thick arrows. Top left: Brown punctate staining is visible 
indicating cells positive for high risk HPV E6/E7 in this case. Top middle: Negative control (DapB) 
of this case shows no staining confirming a true result in the top left image. Top right: Magnified 
image of top left clearly shows HPV E6/E7 positive cells. Bottom left: Brown punctate staining is 
visible indicating cells positive for high risk HPV E6/E7 in this case. Bottom middle: Negative 
control (DapB) of this case shows no staining confirming a true result in bottom left image. Bottom 


























Figure 10: High risk HPV E6/E7 RNA expression in a HDP case from the Japanese Cohort (1). 
A. DapB (negative control probe) of this case showing no staining. B. Punctate brown staining in 
cells of the chorionic villous region indicating these are positive for high risk HPV E6/E7 using 















Figure 11: High risk HPV E6/E7 RNA expression in a HDP case from Japanese Cohort (2).  
A. DapB (negative control probe) of this case showing no staining. B. Punctate brown staining in 
cells of the chorionic villous region indicating these are positive for high risk HPV E6/E7 using 






4.3 Low Risk HPV RNAscope®  
Low risk HPV E6/E7 was tested using a probe that can detect ten low risk types on the HDP 
and the control group. In the HDP group (Table 7), low risk E6/E7 was identified in 33% 
of the cases (n=5/15). Of these, three of the cases were diagnosed with PE (33% of the PE 
cases in the HDP group). All of the positive cases in the HDP group (n=5/15) were positive 
in the decidua basalis and chorionic villous, and all with low scores of 1. Two of the cases 
that tested positive for low risk E6/E7 were also positive for signs of villitis (40% of positive 
cases), and three of the positive cases had significant IUGR (2-3 standard deviations in 
growth percentiles for GA). One case expressed both low risk HPV E6/E7 RNA and high 
risk HPV E6/E7 RNA. Again, none of the control cases (n=11) tested positive for low risk 
E6/E7 expression (0%). Examples of low risk HPV E6/E7 RNA expression is shown in 
Figures 12 and 13.  
 
Low risk HPV E6/E7 was more likely expressed in the HDP group compared to the control 
group (Table 7). Using the χ2 test, the presence of high risk E6/E7 expression in the HDP 
cases (n=5/15) versus the control group (n=0/11) was found to be statistically significant 
was found to be statistically significant with a p value of 0.0331 (z=4.540, df=1). The non-

















Table 7: Results of low risk HPV (E6/E7) expression among the Japanese HDP cohort. 
 HDP cases Controls 































Figure 12: Low risk HPV E6/E7 RNA expression in a HDP case from a Japanese HDP Cohort 
(1). 
A. Punctate brown staining in a cells of the chorionic villous region indicating these are positive 
for low risk HPV E6/E7 using RNAscope®. Positive cells denoted by arrows. B. DapB (negative 
























Figure 13: Low risk HPV E6/E7 RNA expression in a HDP case from a Japanese HDP Cohort 
(2). 
Punctate brown staining in a cells of the chorionic villous region indicating these are positive for 







4.4 Location of HPV in infected specimens 
In the above results, we noted that in all the HPV positive cases, both the decidua basalis 
and chorionic villous region were mutually infected with HPV. In situ analysis of HPV 
infected cells allows us to concurrently assess for other pathologies in the tissue. One case 
very clearly depicted cells of columnal formation extending from the tunica externa of a 
maternal blood vessel, similar to how we see cytotrophoblasts behave in early placentation. 
In this term placenta we see they are highly infected with high risk HPV E6/E7 (Figure 14), 
but have not invaded the tunica media or endothelium of the vessel, a finding consistent 
with in vivo studies of HPV’s effects on trophoblasts (135,180).  
 
In another case, a section of decidua basalis infected with both low and high risk HPV 
E6/E7 contained unusually enlarged cells with perinuclear cavitation and thickened cell 
membranes (Figure 15). These cellular changes are known to be caused by HPV in 
squamous epithelial cells of the cervix, in which case this group of changes is called 
koilocytosis (181). Koilocyte-like changes have been described in multiforme tumours of 








Figure 14: High risk HPV E6/E7 expressing RNA near maternal blood vessels in the term 
placenta. 
Cells expressing high risk HPV E6/E7 RNA, visualised using RNAscope®, are extending from the 













Figure 15: Koilocyte-like changes of cells within the decidua basalis of a case positive for high 
HPV E6/E7 using RNAscope®.  
Cells of the decidua basalis showing abnormal changes in cellular architecture such as perinuclear 
cavitation and thickened cell membranes. These changes are often observed in high risk HPV 
infected cervical cells. These cells also exhibit brown punctate staining indicating they are 






4.5 NOTCH2 RNAscope®  
The human NOTCH2 gene probe (ACD) was used to identify NOTCH2 RNA expression in 
situ. We first optimised the assay using placental tissue from a pregnancy complicated with 
HDP with good RNA quality. This case consistently produced a pattern of NOTCH2 
staining where some cells had high RNA expression (Figure 16). At the conclusion of the 
study, and after excluding cases with poor RNA quality, eight cases were examined. One 
case had very poor staining, due to over digestion. Of the seven remaining cases two were 
HDP cases, and one clinically correlated with PE was strongly positive (Figure 17). As with 
the case used for optimisation, we also saw heterogeneity of staining of nearby cells in all 
of these cases. The low number of cases across the two groups (cases and control) means 





















Figure 16: Expressed NOTCH2 visualised using RNAscope® in a case of known HDP. 
Punctate brown staining in cells of the decidua basalis region indicating these are expressing 
NOTCH2 RNA. Left magnification: Showing very low expression of NOTCH2 RNA. Right 













Figure 17: Heterogeneity of expressed NOTCH2 in a case visualised using RNAscope®. 
Punctate brown staining indicating these are expressing NOTCH2 RNA. A: Consistency of 
expression of NOTCH2 in neighbouring cells from one section of the case. B: Heterogeneity in 








4.6 In situ CMIP expression 
A commercially available RNAscope® probe towards CMIP RNA was not available and 
designing a custom probe was outside of the time constraints of this project. Instead CMIP 
was analysed using an IHC assay. Despite efforts to optimise an immunohistochemistry 
assay to detect CMIP in the placenta, positive staining was not detected in positive control 
endometrial tissue as evident with the absence of moderate-intense cytoplasmic staining 
(Figure 18a). Faint staining was evident in endometrium using a lower dilution of the 
primary antibody, but background staining of the same intensity was also evident in plasma 






Figure 18: CMIP antibody results. 
A. CMIP antibody on FFPE endometrial tissue using 1 in 500 dilution and using citrate buffer (E1) 
(as per manufacturer’s instructions) (171). B. CMIP antibody on FFPE endometrial tissue using 1 
in 100 dilution, using citrate buffer (E1) and no enhancer. Very light brown staining visible but not 






5.1 Summary of findings 
The results of our experiments corroborate the initial Slatter et al. findings that HPV has a 
strongly significant presence in placenta from complicated pregnancies, specifically those 
complicated by HDP. In the study of 339 placenta, 253 (75%) were positive for HPV L1 
and those positive were more likely to represent pregnancies with poor clinical outcomes 
(83%). Our findings of high risk HPV E6/E7 in 40% of cases of HDP, adds to the theory 
that HPV is somehow correlated with complications in pregnancy. The presence of high 
risk HPV E6/E7 RNA also suggests that HPV genes are being transcribed and that the virus 
is active in placenta during pregnancy.  
 
HPV E6/E7 RNA from low risk HPV types was also significantly present in cases of HDP 
(HDP= 5/15, Control=0/11; p=0.033). While low risk HPV types do not have the observed 
transforming properties that may predispose cancer as in high risk types, they are still 
known to cause dysfunctional cell proliferation (107,182), and must be considered if a 
pathological association is drawn between HPV and HDP. The combination of these results 
show high and low risk HPV E6/E7 is increased in HDP, and suggests HPV is active in the 
HDP affected placenta. 
 
Cases with HPV E6/E7 RNA never had E6/E7 isolated to the maternal or fetal layers of the 
placenta only. Trophoblasts of all varieties were most likely infected in both layers, as per 
examination of the slides. Although the syncytiotrophoblast has distinctive morphology 
distinguishing cytotrophoblast and the extravillous trophoblast would require combining 
the HPV E6/E7 assay with one that identifies the cell type using specific cell markers in 
situ.  
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5.2 Pathologies of the placenta associated with HPV infection 
As described by Slatter et al. in 2015, the placenta has been shown to exhibit pathologies 
and clinical outcomes in the presence of HPV. Overall, HPV positive placenta had a lower 
gestational age at delivery of 36.9 weeks (95% CI 36·2–37·5), than that of the HPV negative 
group at 38·4 weeks (95% CI 37·4–39·2, P= 0.02). Placenta born pre-term were also more 
than twice as likely to be infected with HPV (odds ratio 2·13, CI 1·1–4·0, P= 0.018). HPV 
was also detected concurrently with; DNA damage/repair responses in the decidua of 64% 
of HPV positive cases (163/253), Lymphohistiocytic Villitis (LHV) in 14% of HPV positive 
cases (35/253), and Sclerosing Villitis (SV) in 22% of HPV positive cases (163/253) (2). 
This plethora of immune cell invasion and subsequent cell damage found in some form 
amongst all of the HPV positive cases presents a strong argument for an HPV-mediated 
immune reaction to native cells of the placenta. These pathologies are also described beyond 
the Slatter et al. paper, in histological and immunohistochemical examination of placenta 
from pregnancies complicated by HDP.  
 
Villitis of unknown etiology (VUE) describes a common finding in term placenta from 
complicated pregnancies where often the damaging T-cells have since disappeared (183). 
In a review of the existing evidence, Tamblyn et al. suggested means of villitis through a 
“graft versus host” like reaction of the maternal immune cells to foetal tissue (183). VUE 
is defined by intravillous lymphohistiocytic cellular infiltrate, with or without the presence 
of sclerosis and fibrin deposition (184). These findings are similar to that of LHV and SV, 
as described above, suggesting an overlap of the clinical diagnoses. VUE is a diagnosis of 
exclusion, requiring first that infectious causes be ruled out adequately (such as TORCH 
infections), but what if HPV is being overlooked as a potential infectious cause of villitis in 
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the placenta, and therefore inducing the damages we often see in histological examination 
of the placenta following a complicated pregnancy? 
 
HPV as a cause of inflammation, HDP as an effect 
In our results we see that both low and high risk HPV E6/E7 is being expressed in term 
placenta. This indicates the infection has been present throughout the growth and 
development of the placenta and foetus. The expression we observed in our term cases is 
lower than that seen in HPV associated CIN lesions and cancer (185) suggesting that 
expression may be higher earlier in pregnancy and reduces as placental growth slows, or 
that expression remains low throughout pregnancy. In trophoblast studies where cells are 
transfected with large amounts of HPV it is often observed that many of these cells proceed 
to apoptosis (131,132,134,135,186). If trophoblasts are infected with HPV in the beginnings 
of endometrial adhesion of the blastocyst, this may be a possible mechanism for the ability 
of HPV to prevent adequate invasion of trophoblasts. Subsequently this would decrease the 
overall remodelling of spiral arteries, leading to restricted blood flow to the foetus later in 
pregnancy. Cells that survive, while being lowly-infected with HPV, may go on to induce 
low level inflammation of the placenta through exhibiting viral RNA and proteins to either 
foetal or maternal immune cells. This low level of inflammation would be observed in the 
patterns of which we see in VUE. As immune function in pregnancy is suppressed through 
Th2 response switching and presence of immune receptors in the placenta downregulated 
(14), this infection may reach critical mass before triggering an acute maternal immune 
response. Signs and symptoms of chronic inflammation resemble those of HDP; 
hypertension, increased liver enzymes, hypercoagulability (187).   
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5.3 Transiency of HPV infection across human cell types 
Without vaccination, 80% of sexually active adults will contract HPV at some point in their 
lifetime (188). However, where previously it was thought HPV would be cleared naturally 
within 1-2 years, it has since been determined that the rate of normal immune clearance for 
the disease is dependent on the stochastic nature of cell function and that HPV exerts 
significant pathogenesis well within this timeframe (122,189). HPV selectively infects cells 
which express heparin-binding proteins, whom are predominantly epithelial cells, and the 
clearance of HPV is often attributed to the natural shedding of this cell layer (89,111,190). 
However, movement into deeper layers, such as epithelial stem cells, contribute to long 
term saliency of infection in these cells. From here, HPV is able to exert long lasting and 
irreversible damage, leading to cell changes and cancerous lesions.  
 
HPV infection found in cell types critical to conception 
We now have evidence that HPV can and will infect the endometrium, decidua basalis and 
trophoblasts, exerting damaging effects on cell function as demonstrated in vitro 
(131,134,135,186,191). Studies allude to the possibility that HPV may be a trigger for 
placental pathology by such as the in vitro experiments of Liu et al. have shown that HPV 
genotypes 6, 11, 16, 18 and 31 replicate readily in trophoblast cell lines. Later it was also 
discovered that in mouse models that HPV-16 infected embryos exhibited less adhesion to 
the endometrium than in controls (135). Of the embryos that did implant, 100% were noted 
to have lost or abnormal adhesion. The study also noted that embryos that implanted were 
viable at the hatched blastocysts stage but remained aggregated in spheres. This is in 
contrast to the control embryo which attached and formed a flattened layer of trophoblast 
cells with giant nuclei and a central core of smaller cells forming the inner cell mass, 
consistent with normal placentation.  
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The HPV infected placenta as a reservoir for chronic immune activation 
Because the placenta is not “shed” until the end of pregnancy or “shedding” as to avoid 
detection by the maternal immune system, then it could be presumed the infection would 
persist in the location of infection in the placenta for the entirety of pregnancy. It is our 
hypothesis that the infected region enveloped in the placenta is persisting due to lowly 
differentiated cells creating prime targets for viral uptake, as well as rapid growth of the 
organ giving way to increasing viral activity and spread. As mentioned previously, beyond 
20 weeks the placenta’s growth slows dramatically. If prevention of normal cell function 
occurs in the early stages of pregnancy, placental function could be compromised and not 
reach the efficiency required to nourish the fetus between 20-40+ weeks of gestation. As 
HDP and IUGR most commonly arise and worsen in this period, they are commonly 
referred to be a result of poor placental function. The key to understanding HPV’s in vivo 
role on the developing placenta may lie in obtaining first and second trimester placenta for 
research. 
 
Understanding the relationship between HPV and pregnancy complications 
As is true of all science- correlation does not mean causation, and this strong association 
between HPV and pregnancy complications may be a confounding factor due to its high 
prevalence in the fertile population. HPV presents further challenges as there are no ideal 
animal models due to HPV being a species specific infection. However, the recent 
mechanistic evidence described in the literature in combination with the high prevalence of 
HPV found in cohorts of complicated pregnancies suggest further research may help to 
understand the true mechanism of HDP.  
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5.4 The spread of HPV; prevention or treatment?  
As with all clinically based research, our motivations are driven by the need for better 
understanding of how an illness works. Once we understand an illness, we are presented 
with a question- is it easier to treat or prevent the illness? Some diseases are unavoidable 
(Type 1 Diabetes Mellitis, Cystic Fibrosis), while some can be prevented through 
appropriately timed and executed health interventions, such as low cholesterol diets for 
prevention of atherosclerosis, or handwashing and quarantine to prevent the spread of 
influenza. HPV, a sexually transmitted illness, could be prevented through the same means 
as championed for other sexually transmitted diseases (Chlamydia, Gonorrhoea) but due to 
the fact that it is a persistent and invasive virus, vaccines has been employed successfully 
to reduce its presence and spread through the population. As of March 2019, the Ministry 
of Health, New Zealand, target for HPV vaccination across all DHB’s was 75%, with 
targeted campaigning employed towards ethnicities with higher rates of HPV induced 
cervical cancer, such as Maori and Pacific Islanders (188).  
 
HPV Vaccination for protection against pregnancy complications 
HPV vaccination has already been shown to have wide-reaching benefits, specifically in 
relation to pregnancy outcomes. Lawton et al. showed a small, but statistically significant 
reduction of the odds of having a pre-term birth (PTB), an outcome highly associated with 
the HDP’s, following just one dose of the vaccine (OR: 0.87; CI 0.78, 0.96) (192). A dose 
response effect was found with each successive dose received decreasing the likelihood of 
PTB. Similarly, in one study where the association showed a twofold increase in having a 
pre-term birth if you are infected with HPV, the researchers hypothesise widespread 
vaccination of both sexes could improve pregnancy outcomes (115). With these results 
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supporting previous findings that HPV infection is overrepresented in complicated 
pregnancies, will the current vaccination schedule reduce this as a finding in the future? 
 
Between 2007 and 2013 the first iteration of the vaccination Gardasil (Merck Sharp and 
Dohme, Kenilworth, NJ, USA) covered four strains of HPV- types 6, 11, 16 and 18. HPV-
6 and HPV-11 are the low risk types most commonly associated with genital warts, while 
HPV-16 and HPV-18 are high risk types associated with 70% of cases of cervical neoplasia 
(193,194). After 2014, the vaccine was re-engineered to cover nine strains of HPV (HPV-
6, HPV-11, HPV-16, HPV-18 HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58) in order 
cover strains found in 20% of other cases of cervical neoplasia (193,194). We did not 
specifically type HPV in these experiments, instead choosing pangenotypic probes for high 
risk and low risk HPV E6/E7. However, with the evidence pointing to a strong association 
between complications in pregnancy and being infected with high or low risk HPV, it will 
be interesting to see whether further evidence emerges that rates of pregnancy 





5.5 Populational distribution of HPV in Japan and New Zealand 
HDP burden of disease in Japan and NZ 
In New Zealand we are lucky to have a maternity system that carefully monitors and 
supports women during pregnancy. This allows for a high rate of capture of cases where 
complications develop. As a result, PE only complicates approximately 3–8% of 
pregnancies in New Zealand (45). This is low compared to the burden of disease worldwide. 
The Screening for Pregnancy Endpoints (SCOPE) international cohort identified that HDP 
together affect about 5–10% of all pregnancies, and a World Health Organization (WHO) 
review identified hypertension as the single leading cause of maternal mortality in 
developed countries, accounting for 16% of maternal deaths (195,196). However, the rate 
of PE in New Zealand is still high compared to other diseases for which New Zealand also 
has a lower burden of disease. In Japan a 2019 study recorded the incidence of HDP as as 
between 2.8-3.4% (197). 
 
HPV burden of disease in Japan and NZ 
In Japan HPV infection rates across the population are reaching all-time highs. Reported as 
high as 23% among cervical cytology specimens from those 25 years of age or younger 
(121). Systematic statistical analyses shows an interesting trend of HPV prevalence among 
age groups, showing a three-fold increase in those <25 years to those between 35-44 years 
of age (Figure 19) (121). This late increase is consistent with evidence of HPV accumulation 
over time with increasing sexual contacts and is also thought to be contributed to by 
reactivation of latent infection (198,199). As well as this, in identified cervical pathology 
irrespective of age, HPV type 16 and 18 prevalence is 1.9% (1.7-2.1, 95%CI) in normal 
cytology, 15.9% (14.4-17.6, 95%CI) in low-grade lesions (CIN-I), 39.0% (37.1-40.9, 95% 








Figure 19: Crude age-specific HPV prevalence (%) and 95% confidence interval in women with 
normal cervical cytology in Japan. 
This graph shows that Japanese women under the age of 34 have between a 12-22% chance of being 
infected with HPV. Younger women (<25 years) have the highest prevalence of HPV, a near three-
fold increase on women aged 35-44 years. The prevalence of HPV increases in those aged over 45 




Of particular concern, HPV vaccination rates in Japan have plummeted following reports 
of unusual symptoms after vaccination. These reports led their Government to suspend its 
recommendation of the vaccine causing a decline to just 1% of girls born in 2001, and 
almost 0% of girls born after 2001, having been immunized (200). This information helps 
to explain the large percentage of the population under 25 years old with HPV infection as 
seen in Figure 19 (121). One other uniquity of Japanese sexual health is that prevalence of 
heterosexual inexperience in adults aged 18–39 years increased from 21.7 to 24.6% for 
women and from 20.0 to 25.8% for men. It was also found that 1 in 10 adults in their thirties 
had not yet had a heterosexual experience (201). This is a point of cultural difference to the 
rest of the developed world.  
 
How sexual behaviour contributes to the spread of HPV 
Globally, of important public health significance is the increase in the lifetime number of 
sexual contacts. The general trend among newer generations is an increase in the number 
of partners across their lifetime (202), and research has shown those who engage with 
multiple sexual partners in a lifetime five times more likely to have unprotected sex (203).  
While access to long acting reversible contraception is better than ever, methods that protect 
against sexually transmitted infections (male and female condoms), use has not increased 
above 30% (204). Hence, without sufficient vaccination coverage, increasing number of 
sexual contacts and lower barrier contraceptive use, could lead to a significant rise in 
transmission of HPV and subsequently a higher burden of disease for cancer, infertility and 




5.6 Association between NOTCH2 expression results and the current literature 
NOTCH2 belongs to a family of proteins responsible for cell signalling and controlling cell 
fate decisions (165). We know from the literature that cases of HDP, namely PE, result from 
abnormal development of the placenta (7,8,13,17,21,38,74). From the methylation data that 
cases in the HDP group had lower methylation (-36%) than that of control cases. Given the 
usually inverse relationship between DNA methylation and gene expression, we would 
presume this may enable the over-expression of NOTCH2 in HDP cases. 
 
In vitro studies of trophoblast cell lines have previously shown when NOTCH2 was 
downregulated in BeWo cells, proliferation was dramatically promoted, while migration 
and invasion were significantly inhibited. Inversely, when NOTCH2 was upregulated in 
JAR cells, proliferation was inhibited, but migration and invasion were promoted (166,167). 
Further to this decreased NOTCH2 expression was observed in western blots in cases of 
early-onset severe PE (168). In our finished slides, a large range of expression between cells 
of close proximity was observed in each case. If our findings are compared to these studies, 
it may be that the significance of the heterogeneity observed in situ is identifying cells with 
lower expression as pathological. More cases and further testing of these cells to identify 
potential differences is needed.  
 
With the heterogeneity of placental tissues an ever-present concern in sequencing studies, 
qualitative analysis of these slides suggest that RNAscope® as an in situ based technique 
could be used to determine which cell types within a tissue are over, under, or non-
expressing. If one cell population is visualised by this assay to have a difference in 
expression to other cell types within a tissue then isolation and specific sequencing of these 
populations may reveal far greater differences than that of whole tissue. 
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5.7 Strengths and limitations of this study 
The specimens were kindly donated by our Japanese collaborator, Dr Ryuji Fukuzwawa, 
and which allowed us the chance to investigate findings from other NZ based cohorts in a 
new study set, however this also led to further limitations. We know that the rates of HPV 
vaccination in Japanese women are almost non-existent (close to 0%), but we did not have 
access to information regarding previous vaccination for HPV in the cases studied. Also of 
significance is that The Japan Society for the Study of Hypertensive disorders in Pregnancy 
(JSSHP) use different guidelines than NZ for diagnosing the HDP’s (Appendix 7.1), 
meaning this would need to be taken into consideration when comparing results between 
countries and internationally (45,205,206).  
 
As a strength to this study, cohort characteristics for the HDP and control groups were 
largely comparable with the exceptions being characteristics mostly influenced by the 
diagnosis of HDP such as prematurity, mode of delivery and deviations of growth 
percentiles (Table 8). 
 
Limitations of this study include that the results are limited by the size of the cohort and the 
groups within it. While we were kindly gifted these samples, had we had the facilities to 
collect our own samples we may have been able to select a better representative cohort for 
this type of study and avoid issues with unknown processing timelines, differing diagnostic 
guidelines between countries and lack of retrospective access to clinical notes. Increasing 
the number of cases would yield higher statistical power and a better reflection of the true 
result. In addition, there was only block of tissue and one cut section from that block tested 
from each case. Processing more sections was time and cost prohibitive however would 
have added more validity to our results. Also, term placentas were collected for this study 
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are known to have a lower quality of RNA due to the circumstances by which a placenta is 
expelled (207–209). For this study cases with poor RNA quality were excluded which also 
reduced the group sizes and statistical power.  
 
After embarking on this project, we quickly discovered that because this method of in situ 
hybridization, RNAscope®, is still rather new, accessibility to research grade probes was 
difficult or expensive. This is especially as our target genes were obscure, having been 
chosen based on deep targeted sequencing results. Designing probes for the particular target 
genes was both time and cost-prohibitive and so we attempted other methods such as the 
CMIP antibody experiment. Furthermore, interpreting methylation differences in situ using 
RNAscope® proved difficult. Further optimisation and/or quantitative analysis software for 
RNAscope® may fix these issues.   
 
One final limitation is that research into HPV-related reproductive pathology, beyond the 
cervix, is a recent endeavour and little is still known about the exact mechanisms HPV 
exerts in this aggregate of cell types and more to this in pregnancy. It is however prudent to 
remember that HPV causes immunosuppression making a patient more susceptible to other 























Table 8: HDP and control group characteristics. 
GROUP CHARACTERISTICS JAPAN HDP   
(N = 15) 
JAPAN CONTROL  
(N = 11) 
   
MATERNAL AGE YEARS 36.1 (4.4) 35 (6.2) 
DELIVERY   
EMERGENCY C SECTION 47% 0 
ELECTIVE C SECTION 33% 9% 
VAGINAL 20% a 91% 
BMI 23.4 (4.6) 21.5 (4.8) 
SMOKING 7% 0% 
GRAVIDA 2 (0-2) 1 (0-1) 
PARITY 1 (0-2) 0 (0-1) 
MISCARRIAGE 0 (0-1) 0 (0-1) 
BABY SEX  (% FEMALE)  35% 64% 
GESTATION WEEKS 36.6 (1.7)  39.2 (1.3) 
X (JAPAN 
PERSONALISED GROWTH CENTILE (NZ) 








In conclusion, this study provides evidence that HPV E6/E7 is expressed in the placenta of 
pregnancies complicated by HDP. HPV could play an active role early in placental 
development and towards pregnancy complications given the molecular consequences 
observed of HPV in cases of HDP. It is most likely this effect is strongest earlier in 
gestation, particularly when the extravillous cytotrophoblast invade into maternal tissues. 
As growth slows after 20 weeks it is also likely that E6/E7 expression present at delivery 
may be different to that present earlier. Given that HPV E6 and E7 were deleterious to 
trophoblast function in vitro, the finding of E6/E7 expression in the trophoblast in early 
placentae suggests HPV in the placenta may affect implantation, including extravillous 
trophoblast invasion, endometrial attachment, and apoptosis. Subsequently poor 
extravillous cytotrophoblast invasion into maternal tissues underpins an inadequate 
uteroplacental blood supply. Therefore, reduced invasion of the extravillous trophoblast as 
caused by one or both of HPV E6 and E7 is one mechanism by which HPV could contribute 
to hypertensive disorders of pregnancy. 
 
The utility of RNAscope® to determine whether there is an association between DNA 
methylation and RNA expression in situ is limited in that it is not a highly quantitative 
technique, however it is useful to identify, and subsequently isolate, cell populations that 
show distinct expression patterns. Visual analysis of the degree of staining in a cell 
population could reveal which cell types are responsible for pathological expression of a 







6. Future directions 
Further research would be needed to understand why transcriptionally active HPV E6/E7, 
of both high and low risk types, is more likely found in placenta associated with PE. HPV 
E6/E7 expression was regional with overall low expression but a larger cohort, more time 
and further development of our assays to reach a cost effective method would also help us 
to quantify HPV expression in cases of HDP compared to controls. To better understand 
how HPV E6 and E7 may be affecting placental function flow cytometry and cell sorting 
could be used to separate out the cell populations with E6/E7 and then transcriptome 
sequencing applied to investigate altered gene expression. Inclusion of an analysis of HPV 
E6/E7 by flow cytometry may better quantify the amount of HPV E6/E7 present to direct 
further experiments. These would be aimed at determining if the E6/E7 present is sufficient 
to affect placental cell function. 
 
Low risk HPV types are significantly less likely to be found in cancerous tumours, more 
often causing benign proliferative lesions. If further research discovers a mechanism by 
which HPV proves causative towards hypertensive disorders of pregnancy, consideration 
of whether low-risk HPV is low risk towards other conditions will be required. If low-risk 
HPV contributes to pregnancy complications determining which low-risk HPV types are 
present will be important. HPV 6 and 11 are the only low risk HPV types vaccinated against 
and currently there is little likelihood that other low risk types will be included in future 
modifications of the HPV vaccine. 
 
Since the changes to the placenta that pre-dispose to HDP and PE occur early in gestation, 
further investigation could also include an analysis of whether HPV E6/E7 is expressed in 
the first trimester placenta.  
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A larger cohort may allow visual analysis of RNAscope® findings to determine a 
relationship between gene expression and DNA methylation differences in situ. For 
research and development it could be used to isolate populations with distinct over or under 
expression of target genes which could then be isolated, through a variety of methods, to 
garner more specific sequencing data. Specificity of DNA methylation differences in cell 
populations of the heterogeneic placenta could lead to discoveries that influence our 
understanding of complications in pregnancy. 
 
Overall, results stemming from this line of research have clinical indications in the fields of 
fertility medicine, obstetrics and neonatal health, as well as helping us to better understand 
the development of the placenta. The costs created by the burden of hypertensive disorders 
of pregnancy far outweigh investment in preventative health campaigning against the 









Appendix 7.1: Comparison of definition and classification of hypertensive disorders of pregnancy between Japan, New Zealand and 
Internationally. 
JSSHP: Japan Society for Study of Hypertension in Pregnancy(205) 
ISSHP: International Society for Study of Hypertension in Pregnancy(206) 
NZMOH: Diagnosis and treatment of Hypertension and PE Clinical Practice Guidelines(45)  
JSSHP (2013) ISSHP (2018) MOH HDP Guidelines (2018) 
Definition of HDP HDP is defined as hypertension (blood 
pressure ≥ 140/90 
mmHg) with or without proteinuria ( ≥ 300 
mg/24 hours) emerging after 20 weeks 
gestation, but resolving up to 12 
weeks postpartum.1–10) HDP is also 
defined as new onset proteinuria ( ≥ 300 
mg/24 hours) in hypertensive women who 
exhibit no proteinuria before 20 weeks 
gestation. 
Systolic blood pressure greater than or equal 
to 140 mmHg and/or Diastolic blood 
pressure greater than or equal to 90 mmHg 
(Korotkoff 5)* 
Systolic blood pressure (sBP) is greater than 
or equal to 140 mmHg or diastolic blood 
pressure (dBP) is greater than or equal to 90 
mmHg, as measured on two or more 
consecutive occasions at least four hours 
apart.* 
Classification of  
Gestational Hypertension 
GH is diagnosed in women whose blood 
pressure reaches ≥ 140/90 mmHg for the 
first time during pregnancy (after 20 
weeks gestation), but without proteinuria. 
Blood pressure normalizes by 12 weeks 
postpartum. 
Gestational hypertension is characterised by 
the new onset of hypertension after 20 
weeks gestation without any maternal or 
foetal features of PE, followed by return of 
blood pressure to normal within 3 months 
post-partum. 
New onset hypertension occurs after 20 
weeks’ gestation (in a woman who had 
normal blood pressure before 20 weeks’ 
gestation) and diastolic blood pressure is ≥90 
mmHg or systolic blood pressure is ≥140 
mmHg, the woman has none of the 
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abnormalities that define PE, her blood 
pressure returns to normal within three 
months after giving birth. 
Classification of  
Pre-eclampsia  
Hypertension (blood pressure ≥ 140 / 90 
mmHg) accompanied with proteinuria 
exceeding 300 mg/24hours emerges for 
the first time after 20 weeks gestation, but 
both symptoms normalize by 12 weeks 
postpartum. 
 
Superimposed PE is diagnosed when a 
woman with chronic hypertension develops 
one or more of the systemic features of PE 
(proteinuria, maternal organ dysfunction) 
after 20 weeks gestation. Similarly, SGA 
occurs more frequently in women with 
chronic hypertension and evidence of foetal 
effect other than SGA eg. oligohydramnios or 
abnormal uterine artery Doppler flows is 
required to diagnose superimposed PE. 
The new onset of hypertension occurs after 
20 weeks’ gestation (in a woman who had 
normal blood pressure before 20 weeks’ 
gestation) or superimposed on pre-existing 
hypertension and one or more of the 
following also develop as new conditions: 
1. Proteinuria 
2. Maternal organ dysfunction (liver 
involvement, renal insufficiency, 
neurological complications, haematological 
complications) 




Superimposed PE is diagnosed in the 
following 
three cases.  
1. New onset proteinuria ( ≥ 300 
mg/24hours) in hypertensive women who 
exhibit no proteinuria before 20 weeks 
gestation.  
2. Hypertension and 
Superimposed PE is diagnosed when a 
woman with chronic hypertension develops 
one or more of the systemic features of PE 
after 20 weeks gestation. Similarly, SGA 
occurs more frequently in women with 
chronic hypertension and evidence of foetal 
effect other than SGA e.g. oligohydramnios 
Hypertension which is superimposed on pre-
existing hypertension but includes the new 
onset factors discussed in the classification 
of PE 
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proteinuria documented antecedent to 
pregnancy and/or detected before 20 
weeks gestation, one or both of which 
progressing after 20 weeks gestation.  
3. Renal disease with proteinuria 
documented antecedent to pregnancy 
and/or detected before 20 weeks 
gestation, which is accompanied with new 
onset hypertension after 20 weeks. 
or abnormal uterine artery Doppler flows is 
required to diagnose superimposed PE. 
Classification of Eclampsia Eclampsia is defined as the onset of 
convulsions in a 
woman with GH that cannot be attributed 
to other causes. 
The seizures are generalized and may 
appear before, 
during, or after labour. 
 
New onset of seizures occurs in association 
with PE. It is a severe manifestation of PE 
and can occur before, during or after birth. It 
can be the presenting feature of PE in some 
women. 
New onset of seizures occurs in association 
with PE. It is a severe manifestation of PE 
and can occur before, during or after birth. It 
can be the presenting feature of PE in some 
women. 
Classification of HELLP 
Syndrome 
HELLP syndrome is 
considered a severe variant of HDP. 
HELLP syndrome represents a subset of 
women with severe PE characterised by 
haemolysis, raised liver enzymes 
(transaminases) and low platelets with or 
without other pre-eclamptic features. Often 
only two of the three components are 
recognisable. 
A variant of severe PE (elements include 
Haemolysis, Elevated Liver enzymes and Low 
Platelet count). In a woman with PE, the 
presence of any of the following is an 
indicator of HELLP:  
8. maternal platelet count of less than 100 
× 109 /L  
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9. elevated transaminases (elevated blood 
concentrations of liver enzymes to twice 
the normal concentration)  
10. microangiopathic haemolytic anaemia 
with red cell fragments on blood film. 
Classification by severity The severity of HDP is assessed by the 
extent of symptoms. Both blood pressure 
and proteinuria are 
dependable indicators of severity. 
Mild HDP 
Blood pressure is ≥ 140/90 mmHg but < 
160/110mmHg after 20 weeks gestation, 
and proteinuria is ≥300mg/24 hours 
without exceeding 2.0 g/24 hours or 3+ 
dipstick. 
Severe HDP 
Blood pressure is ≥ 160/110 mmHg, and 
proteinuria 
exceeds 2.0 g/24 hours or 3+ dipstick. 
A number of features of PE are recognised to 
significantly increase the risk of adverse 
maternal and foetal outcomes and are 
sometimes used to classify severe PE. The 
natural history of PE is to progress at an 
unpredictable rate, at least until delivery, 
and therefore all women with PE should be 
closely monitored.  
 
The recent ISSHP statement suggested there 
was general consensus that factors 
determining severity include difficulty in 
controlling blood pressure and deteriorating 
clinical condition including HELLP syndrome, 
impending eclampsia, worsening 
thrombocytopenia or worsening foetal 
growth restriction while there is less concern 
regarding increasing proteinuria.  
Clinical judgement exercised in defining 
severity of disease. Treatment interventions 
scaled in increasing need to control 
symptoms of disorder. No clear criteria 
recommended.** 
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Classification by onset HDP that emerges earlier than 32 weeks 
gestation is 
referred to as early onset (EO) type, and 
HDP that emerges after 32 weeks 
gestation is referred to as late onset (LO) 
type. 
PE that emerges earlier than 34+0 weeks 
gestation is 
referred to as early onset (EO) and therefore 
PE that emerges at 34+0 weeks gestation or 
after is referred to as late onset (LO). 
PE that emerges earlier than 34+0 weeks 
gestation is 
referred to as early onset (EO) and therefore 
PE that emerges at 34+0 weeks gestation or 
after is referred to as late onset (LO). 
*Distinct lack of need for proteinuria in diagnosis.  
**Likely due to clear recommendations for initiating treatment once diagnosis confirmed.  
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Appendix 7.2: Treatment of pregnancy induced hypertension, pre-eclampsia, eclampsia and HELLP syndrome in the NZ context 
compared. 
 Gestational Hypertension 
(GH) 
Pre-eclampsia Eclampsia HELLP Syndrome 
Treatment Acute Hypertension: 
Administer antihypertensives. 
As outpatient,  
monitor blood pressure P 1-
2x weekly, Proteinuria 
weekly, and for new onset 
symptoms.  
Proceed to PE treatment if 
increase in blood pressure, 
proteinuria or new onset 
symptoms. 
As inpatient, management of 
hypertension with 
antihypertensives, 2x weekly full 
PE bloods. Assess for IUGR, foetal 
cardiotocography daily, monitor 
for new onset symptoms. 
Where management is 
uncontrolled,   
one on one care, hourly vitals, daily 
bloods, daily foetal 
cardiotocography (continuous if 
symptoms of labour), fluid 
restriction, treatment with 
Magnesium Sulphate, 
recommendation for augmentation 
of labour or delivery of baby with 
considerations made around 
gestational age & availability of 
paediatric care. 
As inpatient, one on one care, hourly 
vitals, continuous foetal 
cardiotocography, assess for 
coagulopathies. Immediate delivery 
of the baby. 
Infusion of Magnesium Sulphate and 
anti-convulsant management. 
As inpatient, one on one care, 
hourly vitals, continuous foetal 
cardiotocography , assess for 
coagulopathies. Immediate 
delivery of the baby. 
Platelet transfusion and 
Magnesium Sulphate may also 
been required. 
Information from NZMOH: Diagnosis and treatment of Hypertension and PE Clinical Practice Guidelines(45) 
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Appendix 7.3: Sample names, diagnosis, and gestation at delivery.  
 
SampleCode_long Sample_code Diagnosis Gwks-day   Mat. Age Gest. at birth Birth Weight Gest. at diagnosis Villitis 
Control cases 
Ctl_2_S16_01199 CTL_2  38W2D   27y6m 38W2D 2560 
-0.89 
  
Ctl_3_S16_01247 CTL_3  39W4D   41y3m 39W4D 2765 
-0.56 
  
Ctl_4_S16_01264 CTL_4  40W2D   28y1m 40W2D 2755 
-0.87 
  
Ctl_5_S16_01270 CTL_5  40W1D   27y4m 40W1D 3185 
0.23 
  
Ctl_6_S16_01287 CTL_6  41W0D   36y10m 41W0D 2975 
-0.43 
  
Ctl_7_S16_01415 CTL_7  39W2D   35y6m 39W2D 2805 
-0.94 
  
Ctl_9_S16_01426 CTL_9  40W6D   39y11m 40W6D 3216 
-0.04 
  
Ctl_12_S16_01536 CTL_12  37W5D   41y8m 37W5D 2665 
-0.25 
  
Ctl_13_S17_00140 CTL_13  37W2D   44y4m 37W2D 2790 
0.004 
  
Ctl_14_S17_00205 CTL_14  38W3D   30y7m 38W3D 3126 
0.736 
  
Ctl_15_S17_00558 CTL_15  39W1D   33y6m 39W1D 2815 
-0.45 
  




PET_1_S15_01824 PET_1 S-PE/Severe 32W0D   32y10m 32W0D 1505 
-1.03 
15W1D Yes 
PET_2_S15_01905 PET_2 GH/Severe 39W0D   38y3m 39W0D 3076 
0.353 
34W3D  
PET_3_S15_01932 PET_3 GH/Severe 37W3D   28y1m 37W3D 3006 
0.948 
35W6D  
PET_4_S15_01947 PET_4 PE/Mild 35W5D   34y10m 35W5D 1578 
-2.69 
34W1D  
PET_5_S15_01995 PET_5 GH/Mild 39W   31y7m 39W 3045 
0.24 
38W0D Yes 
PET_6_S15_01996 PET_6 S-PE/Severe  
(Hp-LOS) 
34W1D   37y10m 34W1D 2190 
0.291 
15W4D  
PET_8_S16_00038 PET_8 GH/Mild 37W1D   34y0m 37W1D 2780 
0.09 
30W0D Yes 
PET_10_S16_00883 PET_10 PE/Severe         
  (Hp-E0)  
37W2D   42y0m 37W2D 2535 
-0.75 
33W6D  
PET_11_S16_01197 PET_11 PE/Severe      
   (Hp-L0) 
36W2D   36y7m 36W2D 2620 
0.094 
35W4D  
PET_12_S16_01226 PET_12 PE/severe   
 (HP-LO) 
36W5D     30y9m 36W5D 1543/2216 
(-3.44),    (-1.09) 
36W3D Yes 
PET_14_S16_01449 PET_14 PE/severe    
(HP-L0) 
36W4D   32y7m 36W4D 1532 
-3.41 
33W4D Yes 
PET_15_S16_01757 PET_15 GH/mild  
(h-EOS) 
37W   40y3m 37W 2032 
-2.09 
32W1D  
PET_16_S16_01960 PET_16 GH/Severe 36W3D   40y8m 36W3D 2480 
-0.1 
36W2D  
PET_17_S17_00117 PET_17 PE/severe  
(hp-LO) 
37W4D   40y4m 37W4D 2676/2348 
(-0.19),   (-1.19) 
37W4D Yes 
    Total 15      
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Non-HDP Pathologic cases 
NPIH_1_S16_01225 NPIH_1 IUGR 38W2D   36y11m 38W2D 2000g 
-2.39 
  
NPIH_3_S16_1558 NPIH_3 IUGR 29W1D   35y4m 29W1D 932g 
-1.72 
  
NPIH_4_S16_1824 NPIH_4 IUGR 26W4D   36y7m 26W4D 566g 
-2.54 
  





(-) 38W   30y9m 38W 2930 
-1.25 
  
    Total 5      
    Grand total 32      
 
NB: This table includes ALL samples, including those they were later excluded for poor RNA quality. 
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Appendix 7.4: Decidua basalis and chorionic villous positivity for high risk and low 
risk HPV-individual cases*. 
Sample Code High risk HPV Score 
Decidua      Villous    
Low risk HPV Score 
Decidua      Villous    
Control cases 
CTL_1 0 0 0 0 
CTL_2 0 0 0 0 
CTL_3 0 0 0 0 
CTL_4 0 0 0 0 
CTL_5 0 0 0 0 
CTL_6 0 0 0 0 
CTL_7 0 0 0 0 
CTL_9 0 0 0 0 
CTL_12 0 0 0 0 
CTL_13 0 0 0 0 
CTL_14 0 0 0 0 
CTL_15 0 0 0 0 
HDP Cases 
PET_1 1 2 0 0 
PET_2 0 0 0 0 
PET_3 0 0 0 0 
PET_4 2 2 0 0 
PET_5 0 0 0 0 
PET_6 0 0 1 1 
PET_8 0 0 1 1 
PET_9 0 0 1 1 
PET_10 0 0 0 0 
PET_11 0 0 1 1 
PET_12 0 0 1 1 
PET_14 1 1 0 0 
PET_15 1 2 1 1 
PET_16 2 2 0 0 
PET_17 2 2 0 0 
Non-HDP Pathologic cases 
NPIH_1 2 2 0 0 
NPIH_3 0 0 0 0 
NPIH_4 2 2 0 0 
NPIH_5 1 1 0 0 
NPIH_6 1 1 0 0 
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